PcBaSe Sweden PcBaSe Sweden ext0014-1-1 Swedish National Data Service Svensk nationell datatjänst PcBaSe Sweden PcBaSe Sweden ext0014-1-1 oai:DiVA.org:umu-200119 10.1111/bju.15891 oai:DiVA.org:uu-469825 10.1177/09622802231155010 oai:DiVA.org:umu-97301 10.1016/j.ejca.2014.10.025 oai:gup.ub.gu.se/282793 10.1002/jso.25643 oai:DiVA.org:uu-375806 10.1016/j.juro.2018.09.042 oai:gup.ub.gu.se/281861 10.1111/bju.14666 oai:DiVA.org:uu-422799 10.1097/ju.0000000000001038 oai:gup.ub.gu.se/291260 10.1111/bju.15002 oai:gup.ub.gu.se/302513 10.1371/journal.pone.0244462 oai:DiVA.org:umu-194353 10.1038/s41698-022-00266-8 oai:DiVA.org:umu-194908 10.1016/j.eururo.2022.03.033 oai:DiVA.org:umu-225966 10.1001/jamanetworkopen.2024.14599 oai:DiVA.org:umu-100146 10.1158/1055-9965.Epi-14-0707 oai:DiVA.org:umu-94131 10.3109/0284186x.2014.939299 oai:DiVA.org:uu-336250 10.1002/ijc.30411 oai:DiVA.org:umu-117803 10.1111/bju.13059 oai:DiVA.org:uu-322713 10.1177/1403494817693695 oai:lup.lub.lu.se:8738fe3a-aa6e-4aee-a5c0-5e4b81155eb4 10.1016/j.eururo.2018.06.021 oai:DiVA.org:uu-440131 urn:nbn:se:uu:diva-440131 urn:nbn:se:oru:diva-11781 10.3109/00365590903024577 urn:nbn:se:umu:diva-64959 10.1002/cncr.27672 urn:nbn:se:umu:diva-83102 10.1371/journal.pone.0074492 oai:DiVA.org:uu-306324 10.1371/journal.pone.0110506 oai:DiVA.org:uu-298833 10.1016/j.eururo.2015.12.049 urn:nbn:se:uu:diva-136812 10.1016/j.eururo.2009.03.007 urn:nbn:se:umu:diva-42221 10.1093/jnci/djq265 oai:gup.ub.gu.se/226905 10.1016/j.eururo.2015.08.051 oai:DiVA.org:umu-100281 10.1111/bju.12671 oai:DiVA.org:umu-106339 10.1200/jco.2014.58.2536 oai:DiVA.org:uu-258548 10.1200/jco.2014.59.1792 oai:DiVA.org:uu-257629 10.1016/j.eururo.2014.12.026 oai:DiVA.org:uu-258329 10.1001/jama.2015.6604 oai:DiVA.org:umu-140946 10.1002/jso.24687 oai:gup.ub.gu.se/260469 10.1002/ijc.30480 urn:nbn:se:umu:diva-42202 10.1016/s1470-2045(10)70038-3 urn:nbn:se:umu:diva-63023 10.3109/00365599.2012.691111 urn:nbn:se:umu:diva-93231 10.1111/jsm.12586 urn:nbn:se:uu:diva-235158 10.1016/j.juro.2014.04.098 oai:DiVA.org:umu-121211 10.1007/s00345-014-1464-5 oai:DiVA.org:uu-266032 10.1371/journal.pone.0140598 oai:DiVA.org:uu-299083 10.1016/j.juro.2015.11.040 oai:DiVA.org:uu-309473 10.1016/j.eururo.2016.07.009 oai:DiVA.org:uu-275554 10.3109/21681805.2015.1063083 oai:DiVA.org:uu-297260 10.3109/21681805.2016.1141319 oai:DiVA.org:umu-121207 10.1111/bju.13360 oai:DiVA.org:uu-299764 10.1016/j.eururo.2016.01.040 oai:DiVA.org:umu-142962 10.1016/j.pathol.2017.08.008 oai:DiVA.org:uu-336238 10.1016/j.eururo.2017.06.036 oai:DiVA.org:umu-137623 10.1038/nchembio.2382 oai:DiVA.org:umu-141490 10.1001/jamaoncol.2016.3600 oai:DiVA.org:umu-124521 10.1002/cam4.665 oai:DiVA.org:uu-309998 10.1002/jso.24408 oai:gup.ub.gu.se/253880 10.1200/jco.2016.69.5304 oai:gup.ub.gu.se/239654 10.1080/21681805.2016.1183226 oai:DiVA.org:uu-301011 10.1111/bju.13404 oai:DiVA.org:umu-103710 10.1111/bju.13179 oai:DiVA.org:uu-310736 10.1002/ijc.30403 oai:DiVA.org:uu-282453 10.1002/ijc.29961 oai:DiVA.org:umu-127328 10.1080/0284186x.2016.1234716 oai:prod.swepub.kib.ki.se:136988446 10.1200/jco.2016.70.7794 oai:DiVA.org:umu-111463 10.1016/j.eururo.2015.07.023 oai:DiVA.org:umu-111464 10.1016/j.eururo.2015.07.002 urn:nbn:se:umu:diva-42210 10.1093/jnci/djq154 urn:nbn:se:umu:diva-32693 10.1016/j.eururo.2009.10.035 urn:nbn:se:liu:diva-100498 10.1093/ije/dys068 urn:nbn:se:umu:diva-48494 10.1016/j.ejca.2011.07.009 urn:nbn:se:umu:diva-48428 10.1002/ijc.26022 urn:nbn:se:umu:diva-46324 10.1016/j.eururo.2011.05.047 urn:nbn:se:umu:diva-42197 10.1016/j.juro.2010.06.008 urn:nbn:se:uu:diva-177850 10.1016/j.ejca.2012.01.035 urn:nbn:se:uu:diva-181773 10.1016/j.eururo.2012.02.032 urn:nbn:se:umu:diva-48503 10.1016/j.eururo.2011.09.010 oai:DiVA.org:uu-238797 10.1111/bju.12935 oai:DiVA.org:uu-270447 10.1186/s12911-015-0217-8 urn:nbn:se:umu:diva-42231 10.1016/j.juro.2010.10.061 urn:nbn:se:umu:diva-48431 10.1016/j.ejca.2011.04.022 oai:DiVA.org:uu-270951 10.1016/j.juro.2015.07.082 urn:nbn:se:umu:diva-42219 10.3109/00365599.2010.498793 urn:nbn:se:umu:diva-62782 10.1007/s00228-012-1290-x urn:nbn:se:umu:diva-70195 urn:nbn:se:oru:diva-29151 10.1016/j.ejca.2012.12.018 urn:nbn:se:uu:diva-210941 10.3109/21681805.2013.813962 urn:nbn:se:uu:diva-208651 10.1093/jnci/djt175 urn:nbn:se:uu:diva-207267 10.1136/bmj.f3406 urn:nbn:se:oru:diva-32998 10.1158/1055-9965.Epi-12-1046 urn:nbn:se:uu:diva-210547 10.3109/0284186x.2013.770164 urn:nbn:se:umu:diva-66780 10.1007/s10552-012-0124-6 urn:nbn:se:umu:diva-66402 10.1016/j.eururo.2012.09.041 urn:nbn:se:umu:diva-70196 10.1002/ijc.28057 urn:nbn:se:umu:diva-67379 10.1007/s10552-012-0141-5 urn:nbn:se:oru:diva-56721 10.1016/j.eururo.2012.08.001 urn:nbn:se:umu:diva-87387 10.1016/j.eururo.2013.06.037 urn:nbn:se:umu:diva-82944 10.1097/SLA.0b013e3182975c88 urn:nbn:se:uu:diva-210560 10.1016/j.juro.2013.05.054 urn:nbn:se:uu:diva-228967 10.1016/j.ejca.2014.03.279 urn:nbn:se:uu:diva-235161 10.3109/21681805.2014.892150 oai:gup.ub.gu.se/194778 10.1136/bmj.g1502 oai:DiVA.org:uu-245647 10.1093/jnci/dju007 oai:DiVA.org:uu-218937 10.1016/j.juro.2013.09.034 oai:DiVA.org:umu-91818 10.1007/s10552-014-0393-3 oai:DiVA.org:uu-310024 10.1093/jnci/djw110 oai:DiVA.org:umu-99351 10.1016/j.eururo.2014.06.010 oai:DiVA.org:umu-109383 10.1016/j.eururo.2015.01.009 oai:DiVA.org:uu-304587 10.1111/bju.12874 oai:DiVA.org:umu-111158 10.5665/sleep.4978 oai:DiVA.org:umu-108454 10.1007/s10552-015-0622-4 urn:nbn:se:umu:diva-61185 10.3109/00365599.2012.691110 oai:DiVA.org:umu-85907 10.1016/j.juro.2014.01.109 oai:lup.lub.lu.se:0e9a611c-81d1-4514-b70a-fd2a8bc7cf2c 10.1080/21681805.2016.1194460 oai:DiVA.org:umu-121492 10.1093/ije/dyv305 oai:DiVA.org:umu-130217 10.1111/bju.13458 oai:gup.ub.gu.se/259424 10.1016/j.eururo.2017.04.002 oai:gup.ub.gu.se/255032 10.1016/j.eururo.2016.07.023 oai:lup.lub.lu.se:3f7c3a7c-e814-49c3-bfcf-ba5b4f6960a8 10.1016/j.juro.2016.06.080 oai:DiVA.org:uu-334734 10.1016/j.eururo.2016.10.031 oai:DiVA.org:uu-352560 10.1002/ijc.31256 oai:DiVA.org:umu-114894 10.3109/21681805.2015.1079796 oai:DiVA.org:uu-302231 10.1016/j.eururo.2015.11.036 oai:DiVA.org:uu-300103 10.3109/21681805.2016.1166153 oai:DiVA.org:umu-121204 10.1016/j.eururo.2015.12.013 LIBRIS-ID:oai:DiVA.org:uu-324345 10.1016/j.ijrobp.2017.01.218 urn:nbn:se:umu:diva-42209 10.1200/jco.2010.29.1567 oai:DiVA.org:uu-336233 10.1111/bju.14023 oai:DiVA.org:oru-70618 10.1186/s12874-018-0628-1 oai:DiVA.org:uu-358574 10.1136/bmjopen-2017-020787 oai:DiVA.org:uu-336246 10.1111/bju.13880 oai:DiVA.org:umu-150859 10.1038/s41391-017-0029-2 oai:gup.ub.gu.se/272178 10.1080/21681805.2018.1426039 oai:DiVA.org:umu-146163 10.1186/s12916-018-1019-5 oai:DiVA.org:umu-152192 10.1002/ijc.31587 oai:gup.ub.gu.se/269432 10.1200/jco.2017.76.6907 oai:gup.ub.gu.se/263317 10.1016/j.ejca.2017.10.023 oai:DiVA.org:uu-373222 10.1080/21681805.2018.1512650 oai:gup.ub.gu.se/266666 10.1016/j.eururo.2017.11.039 oai:DiVA.org:uu-352474 10.1371/journal.pone.0195690 oai:gup.ub.gu.se/274909 10.1111/bju.14213 oai:DiVA.org:umu-144548 10.1002/ijc.31272 oai:DiVA.org:umu-145787 10.1002/jso.24816 oai:DiVA.org:umu-157598 10.1007/s10552-018-1093-1 oai:DiVA.org:uu-380435 10.1016/j.eururo.2018.11.022 oai:DiVA.org:umu-161512 10.1186/s12885-019-5846-3 oai:gup.ub.gu.se/291363 10.1136/bmjopen-2019-033944 oai:DiVA.org:uu-381179 10.1111/bju.14563 oai:gup.ub.gu.se/279498 10.3389/fmed.2019.00051 oai:gup.ub.gu.se/288020 10.1080/21681805.2019.1697358 oai:DiVA.org:uu-381093 10.1016/j.ejso.2018.11.015 oai:DiVA.org:uu-379242 10.1080/0284186x.2018.1529427 oai:DiVA.org:oru-75236 10.1093/aje/kwz026 oai:DiVA.org:uu-386444 10.1186/s12911-019-0823-y oai:prod.swepub.kib.ki.se:143474491 10.1080/21681805.2020.1739139 oai:DiVA.org:uu-423872 10.1038/s41391-020-0220-8 oai:DiVA.org:uu-423875 10.1080/0284186x.2020.1730003 oai:DiVA.org:uu-428992 10.1158/1055-9965.Epi-20-0535 oai:DiVA.org:uu-423801 10.1080/21681805.2020.1756402 oai:DiVA.org:uu-429986 10.1371/journal.pone.0241439 oai:DiVA.org:uu-406282 10.1080/21681805.2019.1702093 oai:gup.ub.gu.se/295138 10.1097/ju.0000000000000793 oai:DiVA.org:umu-172173 10.1002/ijc.33150 oai:DiVA.org:uu-420205 10.1186/s12885-020-07036-4 oai:DiVA.org:uu-406002 10.1097/ju.0000000000000451 oai:DiVA.org:oru-81456 10.1080/21681805.2020.1750475 oai:DiVA.org:uu-413915 10.1371/journal.pone.0227552 oai:gup.ub.gu.se/296771 10.1111/bju.15077 oai:DiVA.org:umu-176488 10.3389/fonc.2020.571838 oai:gup.ub.gu.se/299063 10.1093/jncics/pkaa006 oai:DiVA.org:uu-411316 10.1136/bmjopen-2019-032914 oai:gup.ub.gu.se/285911 10.1007/s00345-019-02887-4 oai:DiVA.org:uu-413453 10.1371/journal.pone.0228447 oai:gup.ub.gu.se/294862 10.1186/s12916-020-01606-w oai:gup.ub.gu.se/284520 10.1080/0284186x.2019.1662084 oai:DiVA.org:uu-405337 10.1016/j.eururo.2019.09.027 oai:DiVA.org:uu-441121 10.3390/cancers13040875 oai:DiVA.org:uu-444389 10.1001/jamanetworkopen.2021.9444 oai:gup.ub.gu.se/309212 10.1080/0284186x.2021.1978539 oai:DiVA.org:uu-453480 10.1371/journal.pone.0255239 oai:DiVA.org:umu-178158 10.1080/0284186x.2020.1847321 oai:gup.ub.gu.se/305085 10.1080/21681805.2021.1910341 oai:DiVA.org:uu-460911 10.1371/journal.pone.0255966 oai:DiVA.org:uu-449149 10.1097/ede.0000000000001358 oai:gup.ub.gu.se/302680 10.1080/0284186x.2021.1885058 oai:gup.ub.gu.se/306221 10.1371/journal.pone.0253081 oai:DiVA.org:oru-96241 10.1177/15579883211058606 oai:DiVA.org:uu-460220 10.1186/s12885-021-08941-y oai:DiVA.org:umu-183575 10.1080/21681805.2021.1916072 oai:DiVA.org:umu-189399 10.1093/aje/kwab146 oai:DiVA.org:umu-185639 10.1038/s41598-021-92347-0 oai:gup.ub.gu.se/300926 10.1080/21681805.2020.1851762 oai:DiVA.org:uu-469809 10.1002/sim.8833 oai:DiVA.org:uu-511763 10.1002/cam4.6004 oai:gup.ub.gu.se/314226 10.1080/21681805.2021.2014561 oai:gup.ub.gu.se/322102 10.1080/21681805.2022.2119270 oai:DiVA.org:uu-477725 10.1136/bmjopen-2021-055485 oai:DiVA.org:uu-467399 10.1186/s12894-022-00967-z oai:DiVA.org:uu-459354 10.1111/bju.15533 oai:DiVA.org:uu-474430 10.1080/21681805.2022.2070275 oai:gup.ub.gu.se/319221 10.1111/bju.15769 oai:gup.ub.gu.se/322455 10.1080/0284186x.2021.2023215 oai:DiVA.org:umu-190754 10.1080/21681805.2021.2019304 oai:DiVA.org:umu-198223 10.1158/1055-9965.Epi-22-0159 oai:lup.lub.lu.se:a0abcc69-6e31-4111-9181-4e260206cc67 10.1016/j.eururo.2022.07.005 oai:DiVA.org:uu-482672 10.1001/jamanetworkopen.2022.25600 oai:DiVA.org:uu-471669 10.1371/journal.pone.0277784 oai:DiVA.org:uu-489380 10.1080/21681805.2022.2107069 oai:gup.ub.gu.se/319151 10.1016/j.euros.2022.05.007 oai:DiVA.org:uu-468382 10.1186/s12911-022-01766-0 oai:DiVA.org:uu-486335 10.1016/j.euros.2022.07.010 oai:gup.ub.gu.se/321610 10.1001/jamanetworkopen.2022.31015 oai:DiVA.org:uu-509996 10.1016/j.euros.2023.04.006 oai:DiVA.org:uu-523223 10.1080/0284186x.2023.2269600 oai:DiVA.org:uu-514508 10.1001/jamanetworkopen.2023.36604 oai:DiVA.org:uu-512857 10.1016/j.eururo.2023.04.026 oai:DiVA.org:uu-509286 10.1093/jncics/pkad046 oai:DiVA.org:uu-507636 10.1002/pds.5612 oai:DiVA.org:uu-524282 10.2340/sju.v58.9572 oai:DiVA.org:uu-514507 10.1155/2023/9527920 oai:DiVA.org:uu-491313 10.1038/s41416-022-02091-z oai:DiVA.org:umu-214053 10.1001/jamanetworkopen.2023.30233 oai:DiVA.org:uu-514510 10.1007/s10552-023-01736-5 oai:DiVA.org:uu-492640 10.1016/j.clgc.2022.09.002 oai:DiVA.org:umu-211797 10.1093/jnci/djad008 oai:DiVA.org:uu-492637 10.1016/j.jclinepi.2022.12.008 oai:DiVA.org:uu-515871 10.2340/sju.v59.34803 oai:DiVA.org:uu-533106 10.1016/j.euo.2023.12.007 oai:lup.lub.lu.se:b19cc7e9-17a4-4a3e-b4f4-f4b52fad3739 10.1093/jnci/djad257 10.1016/j.euo.2024.03.012 oai:prod.swepub.kib.ki.se:238683251 10.1007/s00428-024-03810-y oai:prod.swepub.kib.ki.se:237978024 10.1016/j.euo.2023.11.002 oai:DiVA.org:uu-531609 10.1038/s41416-023-02526-1 oai:prod.swepub.kib.ki.se:238505996 10.2340/1651-226x.2024.26189 oai:DiVA.org:uu-534084 10.2340/sju.v59.40001 oai:DiVA.org:umu-224254 10.1111/bju.16362 oai:gup.ub.gu.se/336383 10.1002/ijc.34932 oai:DiVA.org:uu-530586 10.2340/sju.v59.34015 oai:DiVA.org:uu-540054 10.1016/j.jclinepi.2024.111504 oai:DiVA.org:uu-526555 10.1371/journal.pone.0296804 Stattin, Pär Stattin, Pär Garmo, Hans Garmo, Hans Bill-Axelsson, Anna Bill-Axelsson, Anna Gedeborg, Rolf Gedeborg, Rolf Westerberg, Marcus Westerberg, Marcus Swedish National Data Service Svensk nationell datatjänst Health Services Hälso- och sjukvård Therapeutics Behandlingsmetoder Follow-Up Studies Uppföljningsstudier Socioeconomic Factors Socioekonomiska faktorer Urination Disorders Urineringsstörningar Urinary Incontinence Urininkontinens Neoplasms Tumörer Treatment Outcome Behandlingsresultat Biomedical Research Biomedicinsk forskning Cause of Death Dödsorsaker Epidemiology Epidemiologi Classification Klassificering Drug Utilization Läkemedelsförsörjning Prostatic Neoplasms Prostatatumörer Registries Register Sexual Dysfunction, Physiological Sexuell störning, fysiologisk Radiotherapy Strålbehandling Heredity Ärftlighet HEALTH HÄLSA PcBaSe Sweden is a data base for clinical epidemiological prostate cancer research based on linkages between the National Prostate Cancer Register (NPCR) of Sweden, a nationwide population-based quality database and other nationwide registries. In the period 1996-2023, 246 500 cases have been registered in NPCR with detailed data on tumour characteristics and primary treatment available https://statistik.incanet.se/npcr/. In addition, there are five controls per case. By use of the individually unique person identity number, the NPCR has been linked to the Swedish National Cancer Register, the Cause of Death Register, the Prescribed Drug Register, the National Patient Register, and the Acute Myocardial Infarction Register, the Register of the Total Population, the Longitudinal Integration database for health insurance and labour market studies (LISA), the Multi-Generation Register and several other population-based registers. Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base-a refined prostate cancer trajectory, Int J Epidemiol, 2016 Feb;45(1):73-82. Purpose: To provide a platform for prostate cancer research. The data base allows for population-based observational studies with case-control, cohort, or longitudinal case only design that can be used for studies of pertinent issues of clinical importance. PcBaSe Sweden är en databas för klinisk epidemiologisk forskning om prostatacancer som skapats via en länkning mellan Nationella Prostatacancerregistret (NPCR) och andra nationella register. NPCR är ett nationellt populationsbaserat kvalitetsregister som sedan 1996 omfattar i princip alla män som diagnostiserats med prostatacancer i Sverige. Mellan 1996 och 2023 har ca 246 500 män registrerats i NPCR- med uppgifter om tumörkarakteristik och primärbehandling. Mer information finns https://statistik.incanet.se/npcr/. Dessutom finns data på 5 kontroller per fall. Med hjälp av personnummer har NPCR länkats med Cancerregistret, Dödsorsaksregistret, Läkemedelsregistret, Patientregistret, Flergenerationsregistret, Befolkningsregistret och SCB´s Longitudinella integrationsdatabas för försäkring och arbetsmarknadsstudier (LISA). Data som är tillgängliga i PCBaSe innefattar bland annat tumörklassifikation, primärbehandling, dödsorsak, data om öppen och slutenvård, läkemedelsuttagsmönster, socioekonomiska faktorer, och familjär anhopning. Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base-a refined prostate cancer trajectory, Int J Epidemiol, 2016 Feb;45(1):73-82. Syfte: Att tillhandahålla en populationsbaserad studiebas för forskning om prostatacancer. Databasen möjliggör observationsstudier med fall-kontroll eller kohort design som kan användas för studier med viktiga kliniska implikationer. 1996-01-01 2020-12-31 Sweden Sverige IndividualIndividual IndividIndivid Swedish men Svenska män Numeric OtherOther ÖvrigtÖvrigt Access to data through an external actor. Access to data is restricted. Åtkomst till data via extern aktör. Tillgång till data är begränsad. restrictedAccess Orrason AW, Styrke J, Garmo H, Stattin P. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU Int. 2023;131(4):486-93. Orrason AW, Styrke J, Garmo H, Stattin P. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU Int. 2023;131(4):486-93. 10.1111/bju.15891 oai:DiVA.org:umu-200119 2023 oai:DiVA.org:umu-200119 Westerberg M. Estimation in discrete time coarsened multivariate longitudinal models. Stat Methods Med Res. 2023;32(4):806-19. Westerberg M. Estimation in discrete time coarsened multivariate longitudinal models. Stat Methods Med Res. 2023;32(4):806-19. 10.1177/09622802231155010 oai:DiVA.org:uu-469825 2023 oai:DiVA.org:uu-469825 Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101-11. Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101-11. 10.1016/j.ejca.2014.10.025 oai:DiVA.org:umu-97301 2015 oai:DiVA.org:umu-97301 Cazzaniga W, Godtman RA, Carlsson S, Ahlgren G, Johansson E, Robinson D, et al. Population-based, nationwide registration of prostatectomies in Sweden. J Surg Oncol. 2019;120(4):803-12. Cazzaniga W, Godtman RA, Carlsson S, Ahlgren G, Johansson E, Robinson D, et al. Population-based, nationwide registration of prostatectomies in Sweden. J Surg Oncol. 2019;120(4):803-12. 10.1002/jso.25643 oai:gup.ub.gu.se/282793 2019 oai:gup.ub.gu.se/282793 Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P. Defining intermediate risk prostate cancer suitable for active surveillance. J Urol. 2019;201(2):292-9. Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P. Defining intermediate risk prostate cancer suitable for active surveillance. J Urol. 2019;201(2):292-9. 10.1016/j.juro.2018.09.042 oai:DiVA.org:uu-375806 2019 oai:DiVA.org:uu-375806 Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, et al. Androgen deprivation therapy for prostate cancer and risk of dementia. BJU Int. 2019;124(1):87-92. Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, et al. Androgen deprivation therapy for prostate cancer and risk of dementia. BJU Int. 2019;124(1):87-92. 10.1111/bju.14666 oai:gup.ub.gu.se/281861 2019 oai:gup.ub.gu.se/281861 Bonde Miranda T, Garmo H, Stattin P, Robinson D. 5α-reductase inhibitors and risk of prostate cancer death. J Urol. 2020;204(4):714-9. Bonde Miranda T, Garmo H, Stattin P, Robinson D. 5α-reductase inhibitors and risk of prostate cancer death. J Urol. 2020;204(4):714-9. 10.1097/ju.0000000000001038 oai:DiVA.org:uu-422799 2020 oai:DiVA.org:uu-422799 Bratt O, Drevin L, Prütz KG, Carlsson S, Wennberg L, Stattin P. Prostate cancer in kidney transplant recipients - a nationwide register study. BJU Int. 2020;125(5):679-85. Bratt O, Drevin L, Prütz KG, Carlsson S, Wennberg L, Stattin P. Prostate cancer in kidney transplant recipients - a nationwide register study. BJU Int. 2020;125(5):679-85. 10.1111/bju.15002 oai:gup.ub.gu.se/291260 2020 oai:gup.ub.gu.se/291260 Fallara G, Lissbrant IF, Styrke J, Montorsi F, Garmo H, Stattin P. Observational study on time on treatment with abiraterone and enzalutamide. PLoS One. 2020;15(12):e0244462. Fallara G, Lissbrant IF, Styrke J, Montorsi F, Garmo H, Stattin P. Observational study on time on treatment with abiraterone and enzalutamide. PLoS One. 2020;15(12):e0244462. 10.1371/journal.pone.0244462 oai:gup.ub.gu.se/302513 2020 oai:gup.ub.gu.se/302513 Klein RJ, Vertosick E, Sjoberg D, Ulmert D, Rönn AC, Häggström C, et al. Prostate cancer polygenic risk score and prediction of lethal prostate cancer. NPJ Precis Oncol. 2022;6(1):25. Klein RJ, Vertosick E, Sjoberg D, Ulmert D, Rönn AC, Häggström C, et al. Prostate cancer polygenic risk score and prediction of lethal prostate cancer. NPJ Precis Oncol. 2022;6(1):25. 10.1038/s41698-022-00266-8 oai:DiVA.org:umu-194353 2022 oai:DiVA.org:umu-194353 Jochems SHJ, Fritz J, Häggström C, Järvholm B, Stattin P, Stocks T. Smoking and risk of prostate cancer and prostate cancer death: a pooled study. Eur Urol. 2023;83(5):422-31. Jochems SHJ, Fritz J, Häggström C, Järvholm B, Stattin P, Stocks T. Smoking and risk of prostate cancer and prostate cancer death: a pooled study. Eur Urol. 2023;83(5):422-31. 10.1016/j.eururo.2022.03.033 oai:DiVA.org:umu-194908 2023 oai:DiVA.org:umu-194908 Ventimiglia E, Gedeborg R, Styrke J, Robinson D, Stattin P, Garmo H. Natural history of nonmetastatic prostate cancer managed with watchful waiting. JAMA Netw Open. 2024;7(6):e2414599. Ventimiglia E, Gedeborg R, Styrke J, Robinson D, Stattin P, Garmo H. Natural history of nonmetastatic prostate cancer managed with watchful waiting. JAMA Netw Open. 2024;7(6):e2414599. 10.1001/jamanetworkopen.2024.14599 oai:DiVA.org:umu-225966 2024 oai:DiVA.org:umu-225966 Bonn SE, Sjölander A, Lagerros YT, Wiklund F, Stattin P, Holmberg E, et al. Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(1):57-64. Bonn SE, Sjölander A, Lagerros YT, Wiklund F, Stattin P, Holmberg E, et al. Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(1):57-64. 10.1158/1055-9965.Epi-14-0707 oai:DiVA.org:umu-100146 2015 oai:DiVA.org:umu-100146 Tomic K, Berglund A, Robinson D, Hjälm-Eriksson M, Carlsson S, Lambe M, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54(2):158-63. Tomic K, Berglund A, Robinson D, Hjälm-Eriksson M, Carlsson S, Lambe M, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54(2):158-63. 10.3109/0284186x.2014.939299 oai:DiVA.org:umu-94131 2015 oai:DiVA.org:umu-94131 Wilson KM, Markt SC, Fang F, Nordenvall C, Rider JR, Ye W, et al. Snus use, smoking and survival among prostate cancer patients. Int J Cancer. 2016;139(12):2753-9. Wilson KM, Markt SC, Fang F, Nordenvall C, Rider JR, Ye W, et al. Snus use, smoking and survival among prostate cancer patients. Int J Cancer. 2016;139(12):2753-9. 10.1002/ijc.30411 oai:DiVA.org:uu-336250 2016 oai:DiVA.org:uu-336250 Van Hemelrijck M, Folkvaljon Y, Adolfsson J, Akre O, Holmberg L, Garmo H, et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU Int. 2016;117(3):507-14. Van Hemelrijck M, Folkvaljon Y, Adolfsson J, Akre O, Holmberg L, Garmo H, et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU Int. 2016;117(3):507-14. 10.1111/bju.13059 oai:DiVA.org:umu-117803 2016 oai:DiVA.org:umu-117803 Robertson S, Adolfsson J, Stattin P, Sjövall A, Winnersjö R, Hanning M, et al. Waiting times for cancer patients in Sweden: a nationwide population-based study. Scand J Public Health. 2017;45(3):230-7. Robertson S, Adolfsson J, Stattin P, Sjövall A, Winnersjö R, Hanning M, et al. Waiting times for cancer patients in Sweden: a nationwide population-based study. Scand J Public Health. 2017;45(3):230-7. 10.1177/1403494817693695 oai:DiVA.org:uu-322713 2017 oai:DiVA.org:uu-322713 Li W, Middha M, Bicak M, Sjoberg DD, Vertosick E, Dahlin A, et al. Genome-wide scan identifies role for AOX1 in prostate cancer survival. Eur Urol. 2018;74(6):710-9. Li W, Middha M, Bicak M, Sjoberg DD, Vertosick E, Dahlin A, et al. Genome-wide scan identifies role for AOX1 in prostate cancer survival. Eur Urol. 2018;74(6):710-9. 10.1016/j.eururo.2018.06.021 oai:lup.lub.lu.se:8738fe3a-aa6e-4aee-a5c0-5e4b81155eb4 2018 oai:lup.lub.lu.se:8738fe3a-aa6e-4aee-a5c0-5e4b81155eb4 Stattin P, Franck Lissbrant I. Diagnosspecifika översikter är viktiga verktyg för cancervården. Läkartidningen. 2018;115;EYFW. Stattin P, Franck Lissbrant I. Diagnosspecifika översikter är viktiga verktyg för cancervården. Läkartidningen. 2018;115;EYFW. urn:nbn:se:uu:diva-440131 oai:DiVA.org:uu-440131 2018 oai:DiVA.org:uu-440131 Hagel E, Garmo H, Bill-Axelson A, Bratt O, Johansson JE, Adolfsson J, Lambe M, Stattin P. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol. 2009;43(5):342-9. Hagel E, Garmo H, Bill-Axelson A, Bratt O, Johansson JE, Adolfsson J, Lambe M, Stattin P. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol. 2009;43(5):342-9. 10.3109/00365590903024577 urn:nbn:se:oru:diva-11781 2009 urn:nbn:se:oru:diva-11781 Van Hemelrijck M, Drevin L, Holmberg L, Garmo H, Adolfsson J, Stattin P. Primary cancers before and after prostate cancer diagnosis. Cancer. 2012;118(24):6207-16. Van Hemelrijck M, Drevin L, Holmberg L, Garmo H, Adolfsson J, Stattin P. Primary cancers before and after prostate cancer diagnosis. Cancer. 2012;118(24):6207-16. 10.1002/cncr.27672 urn:nbn:se:umu:diva-64959 2012 urn:nbn:se:umu:diva-64959 Van Hemelrijck M, Garmo H, Michaëlsson K, Thorstenson A, Akre O, Stattin P, et al. Mortality following hip fracture in men with prostate cancer. PLoS One. 2013;8(9):e74492. Van Hemelrijck M, Garmo H, Michaëlsson K, Thorstenson A, Akre O, Stattin P, et al. Mortality following hip fracture in men with prostate cancer. PLoS One. 2013;8(9):e74492. 10.1371/journal.pone.0074492 urn:nbn:se:umu:diva-83102 2013 urn:nbn:se:umu:diva-83102 Wirén S, Drevin L, Akre O, Robinson D, Stattin P. Fathering of dizygotic twins and risk of prostate cancer: nationwide, population-based case-control study. PLoS One. 2014;9(10):e110506. Wirén S, Drevin L, Akre O, Robinson D, Stattin P. Fathering of dizygotic twins and risk of prostate cancer: nationwide, population-based case-control study. PLoS One. 2014;9(10):e110506. 10.1371/journal.pone.0110506 oai:DiVA.org:uu-306324 2014 oai:DiVA.org:uu-306324 Plym A, Chiesa F, Voss M, Holmberg L, Johansson E, Stattin P, et al. Work disability after robot-assisted or open radical prostatectomy: a nationwide, population-based study. Eur Urol. 2016;70(1):64-71. Plym A, Chiesa F, Voss M, Holmberg L, Johansson E, Stattin P, et al. Work disability after robot-assisted or open radical prostatectomy: a nationwide, population-based study. Eur Urol. 2016;70(1):64-71. 10.1016/j.eururo.2015.12.049 oai:DiVA.org:uu-298833 2016 oai:DiVA.org:uu-298833 Ladjevardi S, Sandblom G, Berglund A, Varenhorst E. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Eur Urol. 2010;57(4):631-8. Ladjevardi S, Sandblom G, Berglund A, Varenhorst E. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Eur Urol. 2010;57(4):631-8. 10.1016/j.eururo.2009.03.007 urn:nbn:se:uu:diva-136812 2010 urn:nbn:se:uu:diva-136812 Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, et al. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst. 2010 Sep 8;102(17):1336-43. Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, et al. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst. 2010 Sep 8;102(17):1336-43. 10.1093/jnci/djq265 urn:nbn:se:umu:diva-42221 2010 urn:nbn:se:umu:diva-42221 Damber JE. Words of wisdom. RE: Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. Eur Urol. 2015;68(6):1102. Damber JE. Words of wisdom. RE: Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. Eur Urol. 2015;68(6):1102. 10.1016/j.eururo.2015.08.051 oai:gup.ub.gu.se/226905 2015 oai:gup.ub.gu.se/226905 Danneman D, Drevin L, Robinson D, Stattin P, Egevad L. Gleason inflation 1998-2011: a registry study of 97,168 men. BJU Int. 2015;115(2):248-55. Danneman D, Drevin L, Robinson D, Stattin P, Egevad L. Gleason inflation 1998-2011: a registry study of 97,168 men. BJU Int. 2015;115(2):248-55. 10.1111/bju.12671 oai:DiVA.org:umu-100281 2015 oai:DiVA.org:umu-100281 Stattin P. Mortality in older men with low-risk prostate cancer and high comorbidity. J Clin Oncol. 2015;33(9):1086-7. Stattin P. Mortality in older men with low-risk prostate cancer and high comorbidity. J Clin Oncol. 2015;33(9):1086-7. 10.1200/jco.2014.58.2536 oai:DiVA.org:umu-106339 2015 oai:DiVA.org:umu-106339 O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243-51. O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243-51. 10.1200/jco.2014.59.1792 oai:DiVA.org:uu-258548 2015 oai:DiVA.org:uu-258548 Bratt O, Folkvaljon Y, Hjälm Eriksson M, Akre O, Carlsson S, Drevin L, et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol. 2015;68(1):53-8. Bratt O, Folkvaljon Y, Hjälm Eriksson M, Akre O, Carlsson S, Drevin L, et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol. 2015;68(1):53-8. 10.1016/j.eururo.2014.12.026 oai:DiVA.org:uu-257629 2015 oai:DiVA.org:uu-257629 Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, et al. Use of Phosphodiesterase Type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA. 2015;313(24):2449-55. Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, et al. Use of Phosphodiesterase Type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA. 2015;313(24):2449-55. 10.1001/jama.2015.6604 oai:DiVA.org:uu-258329 2015 oai:DiVA.org:uu-258329 Fridriksson JÖ, Folkvaljon Y, Lundström KJ, Robinson D, Carlsson S, Stattin P. Long-term adverse effects after retropubic and robot-assisted radical prostatectomy. Nationwide, population-based study. J Surg Oncol. 2017;116(4):500-6. Fridriksson JÖ, Folkvaljon Y, Lundström KJ, Robinson D, Carlsson S, Stattin P. Long-term adverse effects after retropubic and robot-assisted radical prostatectomy. Nationwide, population-based study. J Surg Oncol. 2017;116(4):500-6. 10.1002/jso.24687 oai:DiVA.org:umu-140946 2017 oai:DiVA.org:umu-140946 Häggström C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L, et al. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. Int J Cancer. 2017;140(3):611-7. Häggström C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L, et al. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. Int J Cancer. 2017;140(3):611-7. 10.1002/ijc.30480 oai:gup.ub.gu.se/260469 2017 oai:gup.ub.gu.se/260469 Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, Lambe M, Stattin P, Holmberg L. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 2010 May;11(5):450-8. Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, Lambe M, Stattin P, Holmberg L. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 2010 May;11(5):450-8. 10.1016/s1470-2045(10)70038-3 urn:nbn:se:umu:diva-42202 2010 urn:nbn:se:umu:diva-42202 Carlsson S, Bratt O, Stattin P, Egevad L. Current routines for transrectal ultrasound-guided prostate biopsy: a web-based survey by the Swedish Urology Network. Scand J Urol Nephrol. 2012;46(6):405-10. Carlsson S, Bratt O, Stattin P, Egevad L. Current routines for transrectal ultrasound-guided prostate biopsy: a web-based survey by the Swedish Urology Network. Scand J Urol Nephrol. 2012;46(6):405-10. 10.3109/00365599.2012.691111 urn:nbn:se:umu:diva-63023 2012 urn:nbn:se:umu:diva-63023 Plym A, Folkvaljon Y, Garmo H, Holmberg L, Johansson E, Fransson P, et al. Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancer. J Sex Med. 2014;11(8):2100-8. Plym A, Folkvaljon Y, Garmo H, Holmberg L, Johansson E, Fransson P, et al. Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancer. J Sex Med. 2014;11(8):2100-8. 10.1111/jsm.12586 urn:nbn:se:umu:diva-93231 2014 urn:nbn:se:umu:diva-93231 Lundström KJ, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P, et al. Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol. 2014;192(4):1116-22. Lundström KJ, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P, et al. Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol. 2014;192(4):1116-22. 10.1016/j.juro.2014.04.098 urn:nbn:se:uu:diva-235158 2014 urn:nbn:se:uu:diva-235158 Grotta A, Bottai M, Adami HO, Adams SA, Akre O, Blair SN, et al. Physical activity and body mass index as predictors of prostate cancer risk. World J Urol. 2015;33(10):1495-502. Grotta A, Bottai M, Adami HO, Adams SA, Akre O, Blair SN, et al. Physical activity and body mass index as predictors of prostate cancer risk. World J Urol. 2015;33(10):1495-502. 10.1007/s00345-014-1464-5 oai:DiVA.org:umu-121211 2015 oai:DiVA.org:umu-121211 Robinson D, Garmo H, Stattin P, Michaëlsson K. Risk of fractures and falls during and after 5-α reductase inhibitor use: a nationwide cohort study. PLoS One. 2015;10(10):e0140598. Robinson D, Garmo H, Stattin P, Michaëlsson K. Risk of fractures and falls during and after 5-α reductase inhibitor use: a nationwide cohort study. PLoS One. 2015;10(10):e0140598. 10.1371/journal.pone.0140598 oai:DiVA.org:uu-266032 2015 oai:DiVA.org:uu-266032 Loeb S, Lambe M, Stattin P. Re: Editorial comment on use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma: D. F. Penson J Urol 2015;194:1710-1711. J Urol. 2016;195(4 Pt 1):1172-3. Loeb S, Lambe M, Stattin P. Re: Editorial comment on use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma: D. F. Penson J Urol 2015;194:1710-1711. J Urol. 2016;195(4 Pt 1):1172-3. 10.1016/j.juro.2015.11.040 oai:DiVA.org:uu-299083 2016 oai:DiVA.org:uu-299083 Loeb S, Stattin P. Further evidence against a causal association between erectile dysfunction drugs and melanoma. Eur Urol. 2016;70(5):816-7. Loeb S, Stattin P. Further evidence against a causal association between erectile dysfunction drugs and melanoma. Eur Urol. 2016;70(5):816-7. 10.1016/j.eururo.2016.07.009 oai:DiVA.org:uu-309473 2016 oai:DiVA.org:uu-309473 Stattin P, Sandin F, Sandbäck T, Damber JE, Franck Lissbrant I, Robinson D, et al. Dashboard report on performance on select quality indicators to cancer care providers. Scand J Urol. 2016;50(1):21-8. Stattin P, Sandin F, Sandbäck T, Damber JE, Franck Lissbrant I, Robinson D, et al. Dashboard report on performance on select quality indicators to cancer care providers. Scand J Urol. 2016;50(1):21-8. 10.3109/21681805.2015.1063083 oai:DiVA.org:uu-275554 2016 oai:DiVA.org:uu-275554 Lundström KJ, Folkvaljon Y, Loeb S, Axelson AB, Stattin P, Nordin P. Small bowel obstruction and abdominal pain after robotic versus open radical prostatectomy. Scand J Urol. 2016;50(3):155-9. Lundström KJ, Folkvaljon Y, Loeb S, Axelson AB, Stattin P, Nordin P. Small bowel obstruction and abdominal pain after robotic versus open radical prostatectomy. Scand J Urol. 2016;50(3):155-9. 10.3109/21681805.2016.1141319 oai:DiVA.org:uu-297260 2016 oai:DiVA.org:uu-297260 O'Farrell S, Sandström K, Garmo H, Stattin P, Holmberg L, Adolfsson J, et al. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU Int. 2016;118(3):391-8. O'Farrell S, Sandström K, Garmo H, Stattin P, Holmberg L, Adolfsson J, et al. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU Int. 2016;118(3):391-8. 10.1111/bju.13360 oai:DiVA.org:umu-121207 2016 oai:DiVA.org:umu-121207 Plym A, Voss M, Stattin P, Lambe M. Reply from authors re: Matthew T. Gettman. Assessing work disability after radical prostatectomy. Eur Urol 2016;70:72-3: The challenge of assessing work disability. Eur Urol. 2016;70(1):73-4. Plym A, Voss M, Stattin P, Lambe M. Reply from authors re: Matthew T. Gettman. Assessing work disability after radical prostatectomy. Eur Urol 2016;70:72-3: The challenge of assessing work disability. Eur Urol. 2016;70(1):73-4. 10.1016/j.eururo.2016.01.040 oai:DiVA.org:uu-299764 2016 oai:DiVA.org:uu-299764 Kristiansen A, Drevin L, Delahunt B, Samaratunga H, Robinson D, Franck Lissbrant I, et al. Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. Pathology. 2017;49(7):715-20. Kristiansen A, Drevin L, Delahunt B, Samaratunga H, Robinson D, Franck Lissbrant I, et al. Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. Pathology. 2017;49(7):715-20. 10.1016/j.pathol.2017.08.008 oai:DiVA.org:umu-142962 2017 oai:DiVA.org:umu-142962 Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, et al. Gonadotropin-releasing hormone agonists, orchiectomy, and risk of cardiovascular disease: semi-ecologic, nationwide, population-based study. Eur Urol. 2017;72(6):920-8. Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, et al. Gonadotropin-releasing hormone agonists, orchiectomy, and risk of cardiovascular disease: semi-ecologic, nationwide, population-based study. Eur Urol. 2017;72(6):920-8. 10.1016/j.eururo.2017.06.036 oai:DiVA.org:uu-336238 2017 oai:DiVA.org:uu-336238 Licciardello MP, Ringler A, Markt P, Klepsch F, Lardeau CH, Sdelci S, et al. A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. Nat Chem Biol. 2017;13(7):771-8. Licciardello MP, Ringler A, Markt P, Klepsch F, Lardeau CH, Sdelci S, et al. A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. Nat Chem Biol. 2017;13(7):771-8. 10.1038/nchembio.2382 oai:DiVA.org:umu-137623 2017 oai:DiVA.org:umu-137623 Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P. Uptake of active surveillance for very-low-risk prostate cancer in Sweden. JAMA Oncol. 2017;3(10):1393-8. Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P. Uptake of active surveillance for very-low-risk prostate cancer in Sweden. JAMA Oncol. 2017;3(10):1393-8. 10.1001/jamaoncol.2016.3600 oai:DiVA.org:umu-141490 2017 oai:DiVA.org:umu-141490 Arthur R, Møller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, et al. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med. 2016;5(6):1307-18. Arthur R, Møller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, et al. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med. 2016;5(6):1307-18. 10.1002/cam4.665 oai:DiVA.org:umu-124521 2016 oai:DiVA.org:umu-124521 Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, et al. Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy. J Surg Oncol. 2016;114(6):664-70. Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, et al. Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy. J Surg Oncol. 2016;114(6):664-70. 10.1002/jso.24408 oai:DiVA.org:uu-309998 2016 oai:DiVA.org:uu-309998 Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J Clin Oncol. 2017;35(13):1430-6. Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J Clin Oncol. 2017;35(13):1430-6. 10.1200/jco.2016.69.5304 oai:gup.ub.gu.se/253880 2017 oai:gup.ub.gu.se/253880 Bjartell A, Bottai M, Persson J, Bratt O, Damber JE, Stattin P, et al. Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. Scand J Urol. 2016;50(4):255-9. Bjartell A, Bottai M, Persson J, Bratt O, Damber JE, Stattin P, et al. Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. Scand J Urol. 2016;50(4):255-9. 10.1080/21681805.2016.1183226 oai:gup.ub.gu.se/239654 2016 oai:gup.ub.gu.se/239654 Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, et al. Postoperative mortality 90 days after robot-assisted laparoscopic prostatectomy and retropubic radical prostatectomy: a nationwide population-based study. BJU Int. 2016;118(2):302-6. Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, et al. Postoperative mortality 90 days after robot-assisted laparoscopic prostatectomy and retropubic radical prostatectomy: a nationwide population-based study. BJU Int. 2016;118(2):302-6. 10.1111/bju.13404 oai:DiVA.org:uu-301011 2016 oai:DiVA.org:uu-301011 Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, et al. Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int. 2016;117(6b):E36-45. Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, et al. Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int. 2016;117(6b):E36-45. 10.1111/bju.13179 oai:DiVA.org:umu-103710 2016 oai:DiVA.org:umu-103710 Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, et al. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Int J Cancer. 2016;139(12):2698-704. Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, et al. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Int J Cancer. 2016;139(12):2698-704. 10.1002/ijc.30403 oai:DiVA.org:uu-310736 2016 oai:DiVA.org:uu-310736 Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, et al. Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study. Int J Cancer. 2016;138(9):2154-60. Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, et al. Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study. Int J Cancer. 2016;138(9):2154-60. 10.1002/ijc.29961 oai:DiVA.org:uu-282453 2016 oai:DiVA.org:uu-282453 Tomic K, Westerberg M, Robinson D, Garmo H, Stattin P. Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden. Acta Oncol. 2016;55(12):1461-6. Tomic K, Westerberg M, Robinson D, Garmo H, Stattin P. Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden. Acta Oncol. 2016;55(12):1461-6. 10.1080/0284186x.2016.1234716 oai:DiVA.org:umu-127328 2016 oai:DiVA.org:umu-127328 Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, et al. Effect of comorbidity on prostate cancer-specific mortality: a prospective observational study. J Clin Oncol. 2017;35(31):3566-74. Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, et al. Effect of comorbidity on prostate cancer-specific mortality: a prospective observational study. J Clin Oncol. 2017;35(31):3566-74. 10.1200/jco.2016.70.7794 oai:prod.swepub.kib.ki.se:136988446 2017 oai:prod.swepub.kib.ki.se:136988446 Loeb S, Schlomm T, Stattin P. Associations do not equal causation: clinical relevance of statistical associations of phosphodiesterase type 5 inhibitors with prostate cancer progression and melanoma. Eur Urol. 2015;68(5):754-5. Loeb S, Schlomm T, Stattin P. Associations do not equal causation: clinical relevance of statistical associations of phosphodiesterase type 5 inhibitors with prostate cancer progression and melanoma. Eur Urol. 2015;68(5):754-5. 10.1016/j.eururo.2015.07.023 oai:DiVA.org:umu-111463 2015 oai:DiVA.org:umu-111463 Stattin P, Robinson D, Lambe M. Re: Giorgio Gandaglia, Freddie Bray, Matthew R. Cooperberg, et al. Prostate cancer registries: current status and future directions. Eur Urol 2015;68:e110. Eur Urol. 2015;68(5):e110. Stattin P, Robinson D, Lambe M. Re: Giorgio Gandaglia, Freddie Bray, Matthew R. Cooperberg, et al. Prostate cancer registries: current status and future directions. Eur Urol 2015;68:e110. Eur Urol. 2015;68(5):e110. 10.1016/j.eururo.2015.07.002 oai:DiVA.org:umu-111464 2015 oai:DiVA.org:umu-111464 Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010 Jul 7;102(13):950-8. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010 Jul 7;102(13):950-8. 10.1093/jnci/djq154 urn:nbn:se:umu:diva-42210 2010 urn:nbn:se:umu:diva-42210 Bill-Axelson A, Garmo H, Lambe M, Bratt O, Adolfsson J, Nyberg U, Steineck G, Stattin P. Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden. Eur Urol. 2010 Mar;57(3):390-5. Bill-Axelson A, Garmo H, Lambe M, Bratt O, Adolfsson J, Nyberg U, Steineck G, Stattin P. Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden. Eur Urol. 2010 Mar;57(3):390-5. 10.1016/j.eururo.2009.10.035 urn:nbn:se:umu:diva-32693 2010 urn:nbn:se:umu:diva-32693 Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellström K, Fransson P, et al. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42(4):956-67. Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellström K, Fransson P, et al. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42(4):956-67. 10.1093/ije/dys068 urn:nbn:se:liu:diva-100498 2013 urn:nbn:se:liu:diva-100498 Berglund A, Garmo H, Robinson D, Tishelman C, Holmberg L, Bratt O, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J Cancer. 2012;48(1):75-84. Berglund A, Garmo H, Robinson D, Tishelman C, Holmberg L, Bratt O, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J Cancer. 2012;48(1):75-84. 10.1016/j.ejca.2011.07.009 urn:nbn:se:umu:diva-48494 2012 urn:nbn:se:umu:diva-48494 Robinson D, Garmo H, Lindahl B, Van Hemelrijck M, Adolfsson J, Bratt O, et al. Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden. Int J Cancer. 2012;130(2):478-87. Robinson D, Garmo H, Lindahl B, Van Hemelrijck M, Adolfsson J, Bratt O, et al. Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden. Int J Cancer. 2012;130(2):478-87. 10.1002/ijc.26022 urn:nbn:se:umu:diva-48428 2012 urn:nbn:se:umu:diva-48428 Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol. 2011;60(3):554-63. Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol. 2011;60(3):554-63. 10.1016/j.eururo.2011.05.047 urn:nbn:se:umu:diva-46324 2011 urn:nbn:se:umu:diva-46324 Holmström B, Holmberg E, Egevad L, Adolfsson J, Johansson JE, Hugosson J, et al. Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol. 2010;184(4):1322-7. Holmström B, Holmberg E, Egevad L, Adolfsson J, Johansson JE, Hugosson J, et al. Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol. 2010;184(4):1322-7. 10.1016/j.juro.2010.06.008 urn:nbn:se:umu:diva-42197 2010 urn:nbn:se:umu:diva-42197 Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, Lambe M, et al. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer. 2012;48(11):1672-81. Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, Lambe M, et al. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer. 2012;48(11):1672-81. 10.1016/j.ejca.2012.01.035 urn:nbn:se:uu:diva-177850 2012 urn:nbn:se:uu:diva-177850 Jansson KF, Akre O, Garmo H, Bill-Axelson A, Adolfsson J, Stattin P, et al. Concordance of tumor differentiation among brothers with prostate cancer. Eur Urol. 2012;62(4):656-61. Jansson KF, Akre O, Garmo H, Bill-Axelson A, Adolfsson J, Stattin P, et al. Concordance of tumor differentiation among brothers with prostate cancer. Eur Urol. 2012;62(4):656-61. 10.1016/j.eururo.2012.02.032 urn:nbn:se:uu:diva-181773 2012 urn:nbn:se:uu:diva-181773 Van Hemelrijck M, Garmo H, Holmberg L, Stattin P, Adolfsson J. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden. Eur Urol. 2012;61(4):690-700. Van Hemelrijck M, Garmo H, Holmberg L, Stattin P, Adolfsson J. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden. Eur Urol. 2012;61(4):690-700. 10.1016/j.eururo.2011.09.010 urn:nbn:se:umu:diva-48503 2012 urn:nbn:se:umu:diva-48503 Melvin JC, Garmo H, Daniel R, Shanmugalingam T, Stattin P, Häggström C, et al. An investigation into the relationship between statins and cancer using population-based data. BJU Int. 2015;116(5):681-3. Melvin JC, Garmo H, Daniel R, Shanmugalingam T, Stattin P, Häggström C, et al. An investigation into the relationship between statins and cancer using population-based data. BJU Int. 2015;116(5):681-3. 10.1111/bju.12935 oai:DiVA.org:uu-238797 2015 oai:DiVA.org:uu-238797 Lindhagen L, Van Hemelrijck M, Robinson D, Stattin P, Garmo H. How to model temporal changes in comorbidity for cancer patients using prospective cohort data. BMC Med Inform Decis Mak. 2015;15:96. Lindhagen L, Van Hemelrijck M, Robinson D, Stattin P, Garmo H. How to model temporal changes in comorbidity for cancer patients using prospective cohort data. BMC Med Inform Decis Mak. 2015;15:96. 10.1186/s12911-015-0217-8 oai:DiVA.org:uu-270447 2015 oai:DiVA.org:uu-270447 Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011;185(3):833-9. Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011;185(3):833-9. 10.1016/j.juro.2010.10.061 urn:nbn:se:umu:diva-42231 2011 urn:nbn:se:umu:diva-42231 Bill-Axelson A, Garmo H, Nyberg U, Lambe M, Bratt O, Stattin P, et al. Psychiatric treatment in men with prostate cancer - results from a nation-wide, population-based cohort study from PCBaSe Sweden. Eur J Cancer. 2011;47(14):2195-201. Bill-Axelson A, Garmo H, Nyberg U, Lambe M, Bratt O, Stattin P, et al. Psychiatric treatment in men with prostate cancer - results from a nation-wide, population-based cohort study from PCBaSe Sweden. Eur J Cancer. 2011;47(14):2195-201. 10.1016/j.ejca.2011.04.022 urn:nbn:se:umu:diva-48431 2011 urn:nbn:se:umu:diva-48431 Stattin K, Sandin F, Bratt O, Lambe M. The risk of distant metastases and cancer specific survival in men with serum prostate specific antigen values above 100 ng/ml. J Urol. 2015;194(6):1594-600. Stattin K, Sandin F, Bratt O, Lambe M. The risk of distant metastases and cancer specific survival in men with serum prostate specific antigen values above 100 ng/ml. J Urol. 2015;194(6):1594-600. 10.1016/j.juro.2015.07.082 oai:DiVA.org:uu-270951 2015 oai:DiVA.org:uu-270951 Bratt O, Berglund A, Adolfsson J, Johansson JE, Törnblom M, Stattin P. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden. Scand J Urol Nephrol. 2010;44(6):384-90. Bratt O, Berglund A, Adolfsson J, Johansson JE, Törnblom M, Stattin P. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden. Scand J Urol Nephrol. 2010;44(6):384-90. 10.3109/00365599.2010.498793 urn:nbn:se:umu:diva-42219 2010 urn:nbn:se:umu:diva-42219 Grundmark B, Garmo H, Zethelius B, Stattin P, Lambe M, Holmberg L. Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. Eur J Clin Pharmacol. 2012;68(12):1619-30. Grundmark B, Garmo H, Zethelius B, Stattin P, Lambe M, Holmberg L. Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. Eur J Clin Pharmacol. 2012;68(12):1619-30. 10.1007/s00228-012-1290-x urn:nbn:se:umu:diva-62782 2012 urn:nbn:se:umu:diva-62782 Wirén S, Stattin P. Forskning på kvalitetsregister ger klinisk nytta. Resultat från Nationella prostata­cancerregistret. [Research on quality registries provides clinical benefit. Results from the National Prostate Cancer Registry]. Läkartidningen. 2012;109(26-28):1294-7. Wirén S, Stattin P. Forskning på kvalitetsregister ger klinisk nytta. Resultat från Nationella prostata­cancerregistret. [Research on quality registries provides clinical benefit. Results from the National Prostate Cancer Registry]. Läkartidningen. 2012;109(26-28):1294-7. urn:nbn:se:umu:diva-70195 2012 urn:nbn:se:umu:diva-70195 Carlsson S, Sandin F, Fall K, Lambe M, Adolfsson J, Stattin P, et al. Risk of suicide in men with low-risk prostate cancer. Eur J Cancer. 2013;49(7):1588-99. Carlsson S, Sandin F, Fall K, Lambe M, Adolfsson J, Stattin P, et al. Risk of suicide in men with low-risk prostate cancer. Eur J Cancer. 2013;49(7):1588-99. 10.1016/j.ejca.2012.12.018 urn:nbn:se:oru:diva-29151 2013 urn:nbn:se:oru:diva-29151 Bratt O, Carlsson S, Holmberg E, Holmberg L, Johansson E, Josefsson A, et al. The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scand J Urol. 2013;47(5):347-55. Bratt O, Carlsson S, Holmberg E, Holmberg L, Johansson E, Josefsson A, et al. The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scand J Urol. 2013;47(5):347-55. 10.3109/21681805.2013.813962 urn:nbn:se:uu:diva-210941 2013 urn:nbn:se:uu:diva-210941 Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P. Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst. 2013;105(17):1306-13. Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P. Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst. 2013;105(17):1306-13. 10.1093/jnci/djt175 urn:nbn:se:uu:diva-208651 2013 urn:nbn:se:uu:diva-208651 Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ. 2013;346:f3406. Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ. 2013;346:f3406. 10.1136/bmj.f3406 urn:nbn:se:uu:diva-207267 2013 urn:nbn:se:uu:diva-207267 Fall K, Garmo H, Gudbjörnsdottir S, Stattin P, Zethelius B. Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1102-9. Fall K, Garmo H, Gudbjörnsdottir S, Stattin P, Zethelius B. Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1102-9. 10.1158/1055-9965.Epi-12-1046 urn:nbn:se:oru:diva-32998 2013 urn:nbn:se:oru:diva-32998 Lissbrant IF, Garmo H, Widmark A, Stattin P. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013;52(8):1593-601. Lissbrant IF, Garmo H, Widmark A, Stattin P. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013;52(8):1593-601. 10.3109/0284186x.2013.770164 urn:nbn:se:uu:diva-210547 2013 urn:nbn:se:uu:diva-210547 Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, et al. Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study. Cancer Causes Control. 2013;24(2):383-90. Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, et al. Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study. Cancer Causes Control. 2013;24(2):383-90. 10.1007/s10552-012-0124-6 urn:nbn:se:umu:diva-66780 2013 urn:nbn:se:umu:diva-66780 Van Hemelrijck M, Garmo H, Holmberg L, Bill-Axelson A, Carlsson S, Akre O, et al. Thromboembolic events following surgery for prostate cancer. Eur Urol. 2013;63(2):354-63. Van Hemelrijck M, Garmo H, Holmberg L, Bill-Axelson A, Carlsson S, Akre O, et al. Thromboembolic events following surgery for prostate cancer. Eur Urol. 2013;63(2):354-63. 10.1016/j.eururo.2012.09.041 urn:nbn:se:umu:diva-66402 2013 urn:nbn:se:umu:diva-66402 Wirén SM, Drevin LI, Carlsson SV, Akre O, Holmberg EC, Robinson DE, et al. Fatherhood status and risk of prostate cancer: nationwide, population-based case-control study. Int J Cancer. 2013;133(4):937-43. Wirén SM, Drevin LI, Carlsson SV, Akre O, Holmberg EC, Robinson DE, et al. Fatherhood status and risk of prostate cancer: nationwide, population-based case-control study. Int J Cancer. 2013;133(4):937-43. 10.1002/ijc.28057 urn:nbn:se:umu:diva-70196 2013 urn:nbn:se:umu:diva-70196 Eloranta S, Adolfsson J, Lambert PC, Stattin P, Akre O, Andersson TM, et al. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. Cancer Causes Control. 2013;24(3):505-15. Eloranta S, Adolfsson J, Lambert PC, Stattin P, Akre O, Andersson TM, et al. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. Cancer Causes Control. 2013;24(3):505-15. 10.1007/s10552-012-0141-5 urn:nbn:se:umu:diva-67379 2013 urn:nbn:se:umu:diva-67379 Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol. 2013;63(1):88-96. Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol. 2013;63(1):88-96. 10.1016/j.eururo.2012.08.001 urn:nbn:se:oru:diva-56721 2013 urn:nbn:se:oru:diva-56721 Stattin P, Loeb S. "To measure is to know. If you cannot measure it, you cannot improve it": statistical modeling cannot compensate for unmeasured bias. Eur Urol. 2014;65(4):701-3. Stattin P, Loeb S. "To measure is to know. If you cannot measure it, you cannot improve it": statistical modeling cannot compensate for unmeasured bias. Eur Urol. 2014;65(4):701-3. 10.1016/j.eururo.2013.06.037 urn:nbn:se:umu:diva-87387 2014 urn:nbn:se:umu:diva-87387 Nilsson H, Stranne J, Stattin P, Nordin P. Incidence of groin hernia repair after radical prostatectomy: a population-based nationwide study. Ann Surg. 2014;259(6):1223-7. Nilsson H, Stranne J, Stattin P, Nordin P. Incidence of groin hernia repair after radical prostatectomy: a population-based nationwide study. Ann Surg. 2014;259(6):1223-7. 10.1097/SLA.0b013e3182975c88 urn:nbn:se:umu:diva-82944 2014 urn:nbn:se:umu:diva-82944 Loeb S, Berglund A, Stattin P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol. 2013;190(5):1742-9. Loeb S, Berglund A, Stattin P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol. 2013;190(5):1742-9. 10.1016/j.juro.2013.05.054 urn:nbn:se:uu:diva-210560 2013 urn:nbn:se:uu:diva-210560 Lycken M, Garmo H, Adolfsson J, Stattin P, Holmberg L, Bill-Axelson A. Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study. Eur J Cancer. 2014;50(10):1789-98. Lycken M, Garmo H, Adolfsson J, Stattin P, Holmberg L, Bill-Axelson A. Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study. Eur J Cancer. 2014;50(10):1789-98. 10.1016/j.ejca.2014.03.279 urn:nbn:se:uu:diva-228967 2014 urn:nbn:se:uu:diva-228967 Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, Stattin P. Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories. Scand J Urol. 2014;48(5):426-35. Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, Stattin P. Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories. Scand J Urol. 2014;48(5):426-35. 10.3109/21681805.2014.892150 urn:nbn:se:uu:diva-235161 2014 urn:nbn:se:uu:diva-235161 Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:g1502. Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:g1502. 10.1136/bmj.g1502 oai:gup.ub.gu.se/194778 2014 oai:gup.ub.gu.se/194778 Stattin P, Carlsson S, Holmström B, Vickers A, Hugosson J, Lilja H, et al. Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst. 2014;106(3):dju007. Stattin P, Carlsson S, Holmström B, Vickers A, Hugosson J, Lilja H, et al. Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst. 2014;106(3):dju007. 10.1093/jnci/dju007 oai:DiVA.org:uu-245647 2014 oai:DiVA.org:uu-245647 Vellekoop A, Loeb S, Folkvaljon Y, Stattin P. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. J Urol. 2014;191(2):350-7. Vellekoop A, Loeb S, Folkvaljon Y, Stattin P. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. J Urol. 2014;191(2):350-7. 10.1016/j.juro.2013.09.034 oai:DiVA.org:uu-218937 2014 oai:DiVA.org:uu-218937 Bonn SE, Wiklund F, Sjölander A, Szulkin R, Stattin P, Holmberg E, et al. Body mass index and weight change in men with prostate cancer: progression and mortality. Cancer Causes Control. 2014;25(8):933-43. Bonn SE, Wiklund F, Sjölander A, Szulkin R, Stattin P, Holmberg E, et al. Body mass index and weight change in men with prostate cancer: progression and mortality. Cancer Causes Control. 2014;25(8):933-43. 10.1007/s10552-014-0393-3 oai:DiVA.org:umu-91818 2014 oai:DiVA.org:umu-91818 Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study. J Natl Cancer Inst. 2016;108(10). Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study. J Natl Cancer Inst. 2016;108(10). 10.1093/jnci/djw110 oai:DiVA.org:uu-310024 2016 oai:DiVA.org:uu-310024 Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P. Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol. 2015;67(2):233-8. Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P. Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol. 2015;67(2):233-8. 10.1016/j.eururo.2014.06.010 oai:DiVA.org:umu-99351 2015 oai:DiVA.org:umu-99351 Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. Eur Urol. 2015;68(2):207-13. Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. Eur Urol. 2015;68(2):207-13. 10.1016/j.eururo.2015.01.009 oai:DiVA.org:umu-109383 2015 oai:DiVA.org:umu-109383 Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P. Upper limit of cancer extent on biopsy defining very low-risk prostate cancer. BJU Int. 2015;116(2):213-9. Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P. Upper limit of cancer extent on biopsy defining very low-risk prostate cancer. BJU Int. 2015;116(2):213-9. 10.1111/bju.12874 oai:DiVA.org:uu-304587 2015 oai:DiVA.org:uu-304587 Markt SC, Grotta A, Nyren O, Adami HO, Mucci LA, Valdimarsdottir UA, et al. Insufficient sleep and risk of prostate cancer in a large Swedish cohort. Sleep. 2015;38(9):1405-10. Markt SC, Grotta A, Nyren O, Adami HO, Mucci LA, Valdimarsdottir UA, et al. Insufficient sleep and risk of prostate cancer in a large Swedish cohort. Sleep. 2015;38(9):1405-10. 10.5665/sleep.4978 oai:DiVA.org:umu-111158 2015 oai:DiVA.org:umu-111158 Robinson D, Garmo H, Holmberg L, Stattin P. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer. Cancer Causes Control. 2015;26(9):1289-97. 10.1007/s10552-015-0622-4 Robinson D, Garmo H, Holmberg L, Stattin P. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer. Cancer Causes Control. 2015;26(9):1289-97. 10.1007/s10552-015-0622-4 10.1007/s10552-015-0622-4 oai:DiVA.org:umu-108454 2015 oai:DiVA.org:umu-108454 Fridriksson JÖ, Gunseus K, Stattin P. Information on pros and cons of prostate-specific antigen testing to men prior to blood draw: a study from the National Prostate Cancer Register (NPCR) of Sweden. Scand J Urol Nephrol. 2012;46(5):326-31. Fridriksson JÖ, Gunseus K, Stattin P. Information on pros and cons of prostate-specific antigen testing to men prior to blood draw: a study from the National Prostate Cancer Register (NPCR) of Sweden. Scand J Urol Nephrol. 2012;46(5):326-31. 10.3109/00365599.2012.691110 urn:nbn:se:umu:diva-61185 2012 urn:nbn:se:umu:diva-61185 Fridriksson JÖ, Holmberg E, Adolfsson J, Lambe M, Bill-Axelson A, Carlsson S, et al. Rehospitalization after radical prostatectomy in a nationwide, population based study. J Urol. 2014;192(1):112-9. Fridriksson JÖ, Holmberg E, Adolfsson J, Lambe M, Bill-Axelson A, Carlsson S, et al. Rehospitalization after radical prostatectomy in a nationwide, population based study. J Urol. 2014;192(1):112-9. 10.1016/j.juro.2014.01.109 oai:DiVA.org:umu-85907 2014 oai:DiVA.org:umu-85907 Fridriksson JÖ, Folkvaljon Y, Nilsson P, Robinson D, Franck-Lissbrant I, Ehdaie B, et al. Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study. Scand J Urol. 2016;50(5):338-45. Fridriksson JÖ, Folkvaljon Y, Nilsson P, Robinson D, Franck-Lissbrant I, Ehdaie B, et al. Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study. Scand J Urol. 2016;50(5):338-45. 10.1080/21681805.2016.1194460 oai:lup.lub.lu.se:0e9a611c-81d1-4514-b70a-fd2a8bc7cf2c 2016 oai:lup.lub.lu.se:0e9a611c-81d1-4514-b70a-fd2a8bc7cf2c Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort profile update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base - a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73-82. Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort profile update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base - a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73-82. 10.1093/ije/dyv305 oai:DiVA.org:umu-121492 2016 oai:DiVA.org:umu-121492 Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, et al. Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012. BJU Int. 2017;119(1):50-6. Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, et al. Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012. BJU Int. 2017;119(1):50-6. 10.1111/bju.13458 oai:DiVA.org:umu-130217 2017 oai:DiVA.org:umu-130217 Sooriakumaran P, Nyberg T, Akre O, Widmark A, Hamdy F, Graefen M, et al. Survival among men at high risk of disseminated prostate cancer receiving initial locally directed radical treatment or initial androgen deprivation therapy. Eur Urol. 2017;72(3):345-51. Sooriakumaran P, Nyberg T, Akre O, Widmark A, Hamdy F, Graefen M, et al. Survival among men at high risk of disseminated prostate cancer receiving initial locally directed radical treatment or initial androgen deprivation therapy. Eur Urol. 2017;72(3):345-51. 10.1016/j.eururo.2017.04.002 oai:gup.ub.gu.se/259424 2017 oai:gup.ub.gu.se/259424 Stattin P, Sandin F, Thomsen FB, Garmo H, Robinson D, Lissbrant IF, et al. Association of radical local treatment with mortality in men with very high-risk prostate cancer: a semiecologic, nationwide, population-based study. Eur Urol. 2017;72(1):125-34. Stattin P, Sandin F, Thomsen FB, Garmo H, Robinson D, Lissbrant IF, et al. Association of radical local treatment with mortality in men with very high-risk prostate cancer: a semiecologic, nationwide, population-based study. Eur Urol. 2017;72(1):125-34. 10.1016/j.eururo.2016.07.023 oai:gup.ub.gu.se/255032 2017 oai:gup.ub.gu.se/255032 Thorstenson A, Garmo H, Adolfsson J, Bratt O. Cancer specific mortality in men diagnosed with prostate cancer before age 50 years: a nationwide population based study. J Urol. 2017;197(1):61-6. Thorstenson A, Garmo H, Adolfsson J, Bratt O. Cancer specific mortality in men diagnosed with prostate cancer before age 50 years: a nationwide population based study. J Urol. 2017;197(1):61-6. 10.1016/j.juro.2016.06.080 oai:lup.lub.lu.se:3f7c3a7c-e814-49c3-bfcf-ba5b4f6960a8 2017 oai:lup.lub.lu.se:3f7c3a7c-e814-49c3-bfcf-ba5b4f6960a8 Van Hemelrijck M, Garmo H, Lindhagen L, Bratt O, Stattin P, Adolfsson J. Quantifying the transition from active surveillance to watchful waiting among men with very low-risk prostate cancer. Eur Urol. 2017;72(4):534-41. Van Hemelrijck M, Garmo H, Lindhagen L, Bratt O, Stattin P, Adolfsson J. Quantifying the transition from active surveillance to watchful waiting among men with very low-risk prostate cancer. Eur Urol. 2017;72(4):534-41. 10.1016/j.eururo.2016.10.031 oai:DiVA.org:uu-334734 2017 oai:DiVA.org:uu-334734 Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, et al. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study. Int J Cancer. 2018;142(11):2254-62. Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, et al. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study. Int J Cancer. 2018;142(11):2254-62. 10.1002/ijc.31256 oai:DiVA.org:uu-352560 2018 oai:DiVA.org:uu-352560 Jan M, Bonn SE, Sjölander A, Wiklund F, Stattin P, Holmberg E, et al. The roles of stress and social support in prostate cancer mortality. Scand J Urol. 2016;50(1):47-55. Jan M, Bonn SE, Sjölander A, Wiklund F, Stattin P, Holmberg E, et al. The roles of stress and social support in prostate cancer mortality. Scand J Urol. 2016;50(1):47-55. 10.3109/21681805.2015.1079796 oai:DiVA.org:umu-114894 2016 oai:DiVA.org:umu-114894 Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. Evaluation of the 2015 Gleason grade groups in a nationwide population-based cohort. Eur Urol. 2016;69(6):1135-41. Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. Evaluation of the 2015 Gleason grade groups in a nationwide population-based cohort. Eur Urol. 2016;69(6):1135-41. 10.1016/j.eururo.2015.11.036 oai:DiVA.org:uu-302231 2016 oai:DiVA.org:uu-302231 Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, et al. Immediate versus delayed prostatectomy: Nationwide population-based study. Scand J Urol. 2016;50(4):246-54. Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, et al. Immediate versus delayed prostatectomy: Nationwide population-based study. Scand J Urol. 2016;50(4):246-54. 10.3109/21681805.2016.1166153 oai:DiVA.org:uu-300103 2016 oai:DiVA.org:uu-300103 Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P. Phosphodiesterase type 5 inhibitor use and disease recurrence after prostate cancer treatment. Eur Urol. 2016;70(5):824-8. Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P. Phosphodiesterase type 5 inhibitor use and disease recurrence after prostate cancer treatment. Eur Urol. 2016;70(5):824-8. 10.1016/j.eururo.2015.12.013 oai:DiVA.org:umu-121204 2016 oai:DiVA.org:umu-121204 Bosco C, Garmo H, Adolfsson J, Stattin P, Holmberg L, Nilsson P, et al. Prostate cancer radiation therapy and risk of thromboembolic events. Int J Radiat Oncol Biol Phys. 2017;97(5):1026-31. Bosco C, Garmo H, Adolfsson J, Stattin P, Holmberg L, Nilsson P, et al. Prostate cancer radiation therapy and risk of thromboembolic events. Int J Radiat Oncol Biol Phys. 2017;97(5):1026-31. 10.1016/j.ijrobp.2017.01.218 LIBRIS-ID:oai:DiVA.org:uu-324345 2017 LIBRIS-ID:oai:DiVA.org:uu-324345 Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol. 2010;28(21):3448-56. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol. 2010;28(21):3448-56. 10.1200/jco.2010.29.1567 urn:nbn:se:umu:diva-42209 2010 urn:nbn:se:umu:diva-42209 Bosco C, Wong C, Garmo H, Crawley D, Holmberg L, Hammar N, et al. Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists. BJU Int. 2018;121(2):260-7. Bosco C, Wong C, Garmo H, Crawley D, Holmberg L, Hammar N, et al. Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists. BJU Int. 2018;121(2):260-7. 10.1111/bju.14023 oai:DiVA.org:uu-336233 2018 oai:DiVA.org:uu-336233 Carlsson J, Davidsson S, Fridfeldt J, Giunchi F, Fiano V, Grasso C, et al. Quantity and quality of nucleic acids extracted from archival formalin fixed paraffin embedded prostate biopsies. BMC Med Res Methodol. 2018;18(1):161. Carlsson J, Davidsson S, Fridfeldt J, Giunchi F, Fiano V, Grasso C, et al. Quantity and quality of nucleic acids extracted from archival formalin fixed paraffin embedded prostate biopsies. BMC Med Res Methodol. 2018;18(1):161. 10.1186/s12874-018-0628-1 oai:DiVA.org:oru-70618 2018 oai:DiVA.org:oru-70618 Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Armes J, et al. Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study. BMJ Open. 2018;8(3):e020787. Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Armes J, et al. Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study. BMJ Open. 2018;8(3):e020787. 10.1136/bmjopen-2017-020787 oai:DiVA.org:uu-358574 2018 oai:DiVA.org:uu-358574 Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Holmberg L, et al. Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer. BJU Int. 2018;121(2):209-16. Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Holmberg L, et al. Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer. BJU Int. 2018;121(2):209-16. 10.1111/bju.13880 oai:DiVA.org:uu-336246 2018 oai:DiVA.org:uu-336246 FitzGerald LM, Zhao S, Leonardson A, Geybels MS, Kolb S, Lin DW, et al. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis. 2018;21(2):228-37. FitzGerald LM, Zhao S, Leonardson A, Geybels MS, Kolb S, Lin DW, et al. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis. 2018;21(2):228-37. 10.1038/s41391-017-0029-2 oai:DiVA.org:umu-150859 2018 oai:DiVA.org:umu-150859 Franck Lissbrant I, Ventimiglia E, Robinson D, Törnblom M, Hjälm-Eriksson M, Lambe M, et al. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. Scand J Urol. 2018;52(2):143-50. Franck Lissbrant I, Ventimiglia E, Robinson D, Törnblom M, Hjälm-Eriksson M, Lambe M, et al. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. Scand J Urol. 2018;52(2):143-50. 10.1080/21681805.2018.1426039 oai:gup.ub.gu.se/272178 2018 oai:gup.ub.gu.se/272178 Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, et al. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Med. 2018;16(1):31. Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, et al. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Med. 2018;16(1):31. 10.1186/s12916-018-1019-5 oai:DiVA.org:umu-146163 2018 oai:DiVA.org:umu-146163 Häggström C, Van Hemelrijck M, Garmo H, Robinson D, Stattin P, Rowley M, et al. Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and type 2 diabetes mellitus. Int J Cancer. 2018;143(8):1868-75. Häggström C, Van Hemelrijck M, Garmo H, Robinson D, Stattin P, Rowley M, et al. Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and type 2 diabetes mellitus. Int J Cancer. 2018;143(8):1868-75. 10.1002/ijc.31587 oai:DiVA.org:umu-152192 2018 oai:DiVA.org:umu-152192 Jansson F, Drevin L, Frisell T, Stattin P, Bratt O, Akre O. Concordance of non-low-risk disease among pairs of brothers with prostate cancer. J Clin Oncol. 2018;36(18):1847-52. Jansson F, Drevin L, Frisell T, Stattin P, Bratt O, Akre O. Concordance of non-low-risk disease among pairs of brothers with prostate cancer. J Clin Oncol. 2018;36(18):1847-52. 10.1200/jco.2017.76.6907 oai:gup.ub.gu.se/269432 2018 oai:gup.ub.gu.se/269432 Lycken M, Drevin L, Garmo H, Stattin P, Adolfsson J, Lissbrant IF, et al. The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data. Eur J Cancer. 2018;88:101-8. Lycken M, Drevin L, Garmo H, Stattin P, Adolfsson J, Lissbrant IF, et al. The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data. Eur J Cancer. 2018;88:101-8. 10.1016/j.ejca.2017.10.023 oai:gup.ub.gu.se/263317 2018 oai:gup.ub.gu.se/263317 Nugin H, Folkvaljon Y, Damber JE, Adolfsson J, Robinson D, Stattin P. Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden. Scand J Urol. 2018;52(4):277-84. Nugin H, Folkvaljon Y, Damber JE, Adolfsson J, Robinson D, Stattin P. Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden. Scand J Urol. 2018;52(4):277-84. 10.1080/21681805.2018.1512650 oai:DiVA.org:uu-373222 2018 oai:DiVA.org:uu-373222 Robinson D, Garmo H, Lissbrant IF, Widmark A, Pettersson A, Gunnlaugsson A, et al. Prostate cancer death after radiotherapy or radical prostatectomy: a nationwide population-based observational study. Eur Urol. 2018;73(4):502-11. Robinson D, Garmo H, Lissbrant IF, Widmark A, Pettersson A, Gunnlaugsson A, et al. Prostate cancer death after radiotherapy or radical prostatectomy: a nationwide population-based observational study. Eur Urol. 2018;73(4):502-11. 10.1016/j.eururo.2017.11.039 oai:gup.ub.gu.se/266666 2018 oai:gup.ub.gu.se/266666 Russell B, Garmo H, Beckmann K, Stattin P, Adolfsson J, Van Hemelrijck M. A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0. PLoS One. 2018;13(4):e0195690. Russell B, Garmo H, Beckmann K, Stattin P, Adolfsson J, Van Hemelrijck M. A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0. PLoS One. 2018;13(4):e0195690. 10.1371/journal.pone.0195690 oai:DiVA.org:uu-352474 2018 oai:DiVA.org:uu-352474 Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M. Public online reporting from a nationwide population-based clinical prostate cancer register. BJU Int. 2018;122(1):8-10. Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M. Public online reporting from a nationwide population-based clinical prostate cancer register. BJU Int. 2018;122(1):8-10. 10.1111/bju.14213 oai:gup.ub.gu.se/274909 2018 oai:gup.ub.gu.se/274909 Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer. 2018;142(12):2478-84. Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer. 2018;142(12):2478-84. 10.1002/ijc.31272 oai:DiVA.org:umu-144548 2018 oai:DiVA.org:umu-144548 Ventimiglia E, Folkvaljon Y, Carlsson S, Bratt O, Montorsi F, Volz D, et al. Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery. J Surg Oncol. 2018;117(2):321-7. Ventimiglia E, Folkvaljon Y, Carlsson S, Bratt O, Montorsi F, Volz D, et al. Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery. J Surg Oncol. 2018;117(2):321-7. 10.1002/jso.24816 oai:DiVA.org:umu-145787 2018 oai:DiVA.org:umu-145787 Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, et al. Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study. Cancer Causes Control. 2019;30(2):195-206. Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, et al. Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study. Cancer Causes Control. 2019;30(2):195-206. 10.1007/s10552-018-1093-1 oai:DiVA.org:umu-157598 2019 oai:DiVA.org:umu-157598 Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, et al. Androgen deprivation therapies and changes in comorbidity: a comparison of gonadotropin-releasing hormone agonists and antiandrogen monotherapy as primary therapy in men with high-risk prostate cancer. Eur Urol. 2019;75(4):676-83. Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, et al. Androgen deprivation therapies and changes in comorbidity: a comparison of gonadotropin-releasing hormone agonists and antiandrogen monotherapy as primary therapy in men with high-risk prostate cancer. Eur Urol. 2019;75(4):676-83. 10.1016/j.eururo.2018.11.022 oai:DiVA.org:uu-380435 2019 oai:DiVA.org:uu-380435 Beckmann K, Russell B, Josephs D, Garmo H, Haggstrom C, Holmberg L, et al. Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study. BMC Cancer. 2019;19(1):612. Beckmann K, Russell B, Josephs D, Garmo H, Haggstrom C, Holmberg L, et al. Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study. BMC Cancer. 2019;19(1):612. 10.1186/s12885-019-5846-3 oai:DiVA.org:umu-161512 2019 oai:DiVA.org:umu-161512 Bergengren O, Garmo H, Bratt O, Holmberg L, Johansson E, Bill-Axelson A. Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study. BMJ Open. 2019;9(12):e033944. Bergengren O, Garmo H, Bratt O, Holmberg L, Johansson E, Bill-Axelson A. Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study. BMJ Open. 2019;9(12):e033944. 10.1136/bmjopen-2019-033944 oai:gup.ub.gu.se/291363 2019 oai:gup.ub.gu.se/291363 Cazzaniga W, Garmo H, Robinson D, Holmberg L, Bill-Axelson A, Stattin P. Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study. BJU Int. 2019;123(3):421-8. Cazzaniga W, Garmo H, Robinson D, Holmberg L, Bill-Axelson A, Stattin P. Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study. BJU Int. 2019;123(3):421-8. 10.1111/bju.14563 oai:DiVA.org:uu-381179 2019 oai:DiVA.org:uu-381179 Cazzaniga W, Ventimiglia E, Alfano M, Robinson D, Lissbrant IF, Carlsson S, et al. Mini review on the use of clinical cancer registers for prostate cancer: The National Prostate Cancer Register (NPCR) of Sweden. Front Med (Lausanne). 2019;6:51. Cazzaniga W, Ventimiglia E, Alfano M, Robinson D, Lissbrant IF, Carlsson S, et al. Mini review on the use of clinical cancer registers for prostate cancer: The National Prostate Cancer Register (NPCR) of Sweden. Front Med (Lausanne). 2019;6:51. 10.3389/fmed.2019.00051 oai:gup.ub.gu.se/279498 2019 oai:gup.ub.gu.se/279498 Godtman RA, Månsson M, Bratt O, Robinsson D, Johansson E, Stattin P, et al. Development and validation of a prediction model for identifying men with intermediate- or high-risk prostate cancer for whom bone imaging is unnecessary: a nation-wide population-based study. Scand J Urol. 2019;53(6):378-84. Godtman RA, Månsson M, Bratt O, Robinsson D, Johansson E, Stattin P, et al. Development and validation of a prediction model for identifying men with intermediate- or high-risk prostate cancer for whom bone imaging is unnecessary: a nation-wide population-based study. Scand J Urol. 2019;53(6):378-84. 10.1080/21681805.2019.1697358 oai:gup.ub.gu.se/288020 2019 oai:gup.ub.gu.se/288020 Sverrisson I, Folkvaljon F, Chabok A, Stattin P, Smedh K, Nikberg M. Anastomotic leakage after anterior resection in patients with rectal cancer previously irradiated for prostate cancer. Eur J Surg Oncol. 2019;45(3):341-6. Sverrisson I, Folkvaljon F, Chabok A, Stattin P, Smedh K, Nikberg M. Anastomotic leakage after anterior resection in patients with rectal cancer previously irradiated for prostate cancer. Eur J Surg Oncol. 2019;45(3):341-6. 10.1016/j.ejso.2018.11.015 oai:DiVA.org:uu-381093 2019 oai:DiVA.org:uu-381093 Thomsen FB, Bosco C, Garmo H, Adolfsson J, Hammar N, Stattin P, et al. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. Acta Oncol. 2019;58(1):110-8. Thomsen FB, Bosco C, Garmo H, Adolfsson J, Hammar N, Stattin P, et al. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. Acta Oncol. 2019;58(1):110-8. 10.1080/0284186x.2018.1529427 oai:DiVA.org:uu-379242 2019 oai:DiVA.org:uu-379242 Zelic R, Zugna D, Bottai M, Andrén O, Fridfeldt J, Carlsson J, et al. Estimation of relative and absolute risks in a competing-risks setting using a nested case-control study design: Example from the ProMort study. Am J Epidemiol. 2019;188(6):1165-73. Zelic R, Zugna D, Bottai M, Andrén O, Fridfeldt J, Carlsson J, et al. Estimation of relative and absolute risks in a competing-risks setting using a nested case-control study design: Example from the ProMort study. Am J Epidemiol. 2019;188(6):1165-73. 10.1093/aje/kwz026 oai:DiVA.org:oru-75236 2019 oai:DiVA.org:oru-75236 Ventimiglia E, Van Hemelrijck M, Lindhagen L, Stattin P, Garmo H. How to measure temporal changes in care pathways for chronic diseases using health care registry data. BMC Med Inform Decis Mak. 2019;19(1):103. Ventimiglia E, Van Hemelrijck M, Lindhagen L, Stattin P, Garmo H. How to measure temporal changes in care pathways for chronic diseases using health care registry data. BMC Med Inform Decis Mak. 2019;19(1):103. 10.1186/s12911-019-0823-y oai:DiVA.org:uu-386444 2019 oai:DiVA.org:uu-386444 Aly M, Leval A, Schain F, Liwing J, Lawson J, Vágó E, et al. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. Scand J Urol. 2020;54(2):115-21. Aly M, Leval A, Schain F, Liwing J, Lawson J, Vágó E, et al. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. Scand J Urol. 2020;54(2):115-21. 10.1080/21681805.2020.1739139 oai:prod.swepub.kib.ki.se:143474491 2020 oai:prod.swepub.kib.ki.se:143474491 Beckmann K, Garmo H, Lindahl B, Holmberg L, Stattin P, Adolfsson J, et al. Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer Prostatic Dis. 2020;23(3):527-33. Beckmann K, Garmo H, Lindahl B, Holmberg L, Stattin P, Adolfsson J, et al. Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer Prostatic Dis. 2020;23(3):527-33. 10.1038/s41391-020-0220-8 oai:DiVA.org:uu-423872 2020 oai:DiVA.org:uu-423872 Beckmann K, Garmo H, Nilsson P, Franck Lissbrant I, Widmark A, Stattin P. Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998-2016. Acta Oncol. 2020;59(5):549-57. Beckmann K, Garmo H, Nilsson P, Franck Lissbrant I, Widmark A, Stattin P. Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998-2016. Acta Oncol. 2020;59(5):549-57. 10.1080/0284186x.2020.1730003 oai:DiVA.org:uu-423875 2020 oai:DiVA.org:uu-423875 Crump C, Stattin P, Brooks JD, Stocks T, Sundquist J, Sieh W, et al. Early-life cardiorespiratory fitness and long-term risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2020;29(11):2187-94. Crump C, Stattin P, Brooks JD, Stocks T, Sundquist J, Sieh W, et al. Early-life cardiorespiratory fitness and long-term risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2020;29(11):2187-94. 10.1158/1055-9965.Epi-20-0535 oai:DiVA.org:uu-428992 2020 oai:DiVA.org:uu-428992 Franck Lissbrant I, Hjälm Eriksson M, Lambe M, Törnblom M, Stattin P. Set-up and preliminary results from the Patient-overview Prostate Cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden. Scand J Urol. 2020;54(3):227-34. Franck Lissbrant I, Hjälm Eriksson M, Lambe M, Törnblom M, Stattin P. Set-up and preliminary results from the Patient-overview Prostate Cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden. Scand J Urol. 2020;54(3):227-34. 10.1080/21681805.2020.1756402 oai:DiVA.org:uu-423801 2020 oai:DiVA.org:uu-423801 Gedeborg R, Garmo H, Robinson D, Stattin P. Prescription-based prediction of baseline mortality risk among older men. PLoS One. 2020;15(10):e0241439. Gedeborg R, Garmo H, Robinson D, Stattin P. Prescription-based prediction of baseline mortality risk among older men. PLoS One. 2020;15(10):e0241439. 10.1371/journal.pone.0241439 oai:DiVA.org:uu-429986 2020 oai:DiVA.org:uu-429986 George G, Garmo H, Rudman S, Holmberg L, Robinson D, Stattin P, et al. Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in Prostate Cancer data Base Sweden. Scand J Urol. 2020;54(1):20-6. George G, Garmo H, Rudman S, Holmberg L, Robinson D, Stattin P, et al. Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in Prostate Cancer data Base Sweden. Scand J Urol. 2020;54(1):20-6. 10.1080/21681805.2019.1702093 oai:DiVA.org:uu-406282 2020 oai:DiVA.org:uu-406282 Jansson F, Folkvaljon F, Stattin P, Bratt O, Akre O. Risk of postoperative up staging or upgrading among men with low risk familial prostate cancer. J Urol. 2020;204(1):79-81. Jansson F, Folkvaljon F, Stattin P, Bratt O, Akre O. Risk of postoperative up staging or upgrading among men with low risk familial prostate cancer. J Urol. 2020;204(1):79-81. 10.1097/ju.0000000000000793 oai:gup.ub.gu.se/295138 2020 oai:gup.ub.gu.se/295138 Jochems SHJ, Stattin P, Häggström C, Järvholm B, Orho-Melander M, Wood AM, et al. Height, body mass index and prostate cancer risk and mortality by way of detection and cancer risk category. Int J Cancer. 2020;147(12):3328-38. Jochems SHJ, Stattin P, Häggström C, Järvholm B, Orho-Melander M, Wood AM, et al. Height, body mass index and prostate cancer risk and mortality by way of detection and cancer risk category. Int J Cancer. 2020;147(12):3328-38. 10.1002/ijc.33150 oai:DiVA.org:umu-172173 2020 oai:DiVA.org:umu-172173 Lin E, Garmo H, Van Hemelrijck M, Adolfsson J, Stattin P, Zethelius B, et al. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study. BMC Cancer. 2020;20(1):551. Lin E, Garmo H, Van Hemelrijck M, Adolfsson J, Stattin P, Zethelius B, et al. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study. BMC Cancer. 2020;20(1):551. 10.1186/s12885-020-07036-4 oai:DiVA.org:uu-420205 2020 oai:DiVA.org:uu-420205 Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P. Opioid use after radical prostatectomy: nationwide, population based study in Sweden. J Urol. 2020;203(1):145-50. Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P. Opioid use after radical prostatectomy: nationwide, population based study in Sweden. J Urol. 2020;203(1):145-50. 10.1097/ju.0000000000000451 oai:DiVA.org:uu-406002 2020 oai:DiVA.org:uu-406002 Lycken M, Drevin L, Garmo H, Larsson A, Andrén O, Holmberg L, et al. Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study. Scand J Urol. 2020;54(3):208-14. Lycken M, Drevin L, Garmo H, Larsson A, Andrén O, Holmberg L, et al. Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study. Scand J Urol. 2020;54(3):208-14. 10.1080/21681805.2020.1750475 oai:DiVA.org:oru-81456 2020 oai:DiVA.org:oru-81456 Mehtälä J, Zong J, Vassilev Z, Brobert G, Gabarró MS, Stattin P, et al. Overall survival and second primary malignancies in men with metastatic prostate cancer. PLoS One. 2020;15(2):e0227552. Mehtälä J, Zong J, Vassilev Z, Brobert G, Gabarró MS, Stattin P, et al. Overall survival and second primary malignancies in men with metastatic prostate cancer. PLoS One. 2020;15(2):e0227552. 10.1371/journal.pone.0227552 oai:DiVA.org:uu-413915 2020 oai:DiVA.org:uu-413915 Orrason AW, Westerberg M, Garmo H, Lissbrant IF, Robinson D, Stattin P. Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden. BJU Int. 2020;126(1):142-51. Orrason AW, Westerberg M, Garmo H, Lissbrant IF, Robinson D, Stattin P. Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden. BJU Int. 2020;126(1):142-51. 10.1111/bju.15077 oai:gup.ub.gu.se/296771 2020 oai:gup.ub.gu.se/296771 Parker J, Crawley D, Garmo H, Lindahl B, Styrke J, Adolfsson J, et al. Use of warfarin or direct oral anticoagulants and risk of prostate cancer in PCBaSe: a nationwide case-control study. Front Oncol. 2020;10:571838. Parker J, Crawley D, Garmo H, Lindahl B, Styrke J, Adolfsson J, et al. Use of warfarin or direct oral anticoagulants and risk of prostate cancer in PCBaSe: a nationwide case-control study. Front Oncol. 2020;10:571838. 10.3389/fonc.2020.571838 oai:DiVA.org:umu-176488 2020 oai:DiVA.org:umu-176488 Pettersson A, Alm D, Garmo H, Hjelm Eriksson M, Castellanos E, Åström L, et al. Comparative effectiveness of different radical radiotherapy treatment regimens for prostate cancer: a population-based cohort study. JNCI Cancer Spectr. 2020;4(2):pkaa006. Pettersson A, Alm D, Garmo H, Hjelm Eriksson M, Castellanos E, Åström L, et al. Comparative effectiveness of different radical radiotherapy treatment regimens for prostate cancer: a population-based cohort study. JNCI Cancer Spectr. 2020;4(2):pkaa006. 10.1093/jncics/pkaa006 oai:gup.ub.gu.se/299063 2020 oai:gup.ub.gu.se/299063 Plym A, Clements M, Voss M, Holmberg L, Stattin P, Lambe M. Duration of sick leave after active surveillance, surgery or radiotherapy for localised prostate cancer: a nationwide cohort study. BMJ Open. 2020;10(3):e032914. Plym A, Clements M, Voss M, Holmberg L, Stattin P, Lambe M. Duration of sick leave after active surveillance, surgery or radiotherapy for localised prostate cancer: a nationwide cohort study. BMJ Open. 2020;10(3):e032914. 10.1136/bmjopen-2019-032914 oai:DiVA.org:uu-411316 2020 oai:DiVA.org:uu-411316 Stranne J, Axen E, Franck-Lissbrant I, Fransson P, Frånlund M, Hugosson J, et al. Single institution followed by national implementation of systematic surgical quality control and feedback for radical prostatectomy: a 20-year journey. World J Urol. 2020;38(6):1397-411. Stranne J, Axen E, Franck-Lissbrant I, Fransson P, Frånlund M, Hugosson J, et al. Single institution followed by national implementation of systematic surgical quality control and feedback for radical prostatectomy: a 20-year journey. World J Urol. 2020;38(6):1397-411. 10.1007/s00345-019-02887-4 oai:gup.ub.gu.se/285911 2020 oai:gup.ub.gu.se/285911 Thomsen FB, Westerberg M, Garmo H, Robinson D, Holmberg L, Ulmert HD, et al. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason grade: nationwide, population-based register study. PLoS One. 2020;15(1):e0228447. Thomsen FB, Westerberg M, Garmo H, Robinson D, Holmberg L, Ulmert HD, et al. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason grade: nationwide, population-based register study. PLoS One. 2020;15(1):e0228447. 10.1371/journal.pone.0228447 oai:DiVA.org:uu-413453 2020 oai:DiVA.org:uu-413453 Thurtle D, Bratt O, Stattin P, Pharoah P, Gnanapragasam V. Comparative performance and external validation of the multivariable PREDICT prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe). BMC Med. 2020;18(1):139. Thurtle D, Bratt O, Stattin P, Pharoah P, Gnanapragasam V. Comparative performance and external validation of the multivariable PREDICT prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe). BMC Med. 2020;18(1):139. 10.1186/s12916-020-01606-w oai:gup.ub.gu.se/294862 2020 oai:gup.ub.gu.se/294862 Westerberg M, Franck Lissbrant I, Damber JE, Robinson D, Garmo H, Stattin P. Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study. Acta Oncol. 2020;59(1):106-11. Westerberg M, Franck Lissbrant I, Damber JE, Robinson D, Garmo H, Stattin P. Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study. Acta Oncol. 2020;59(1):106-11. 10.1080/0284186x.2019.1662084 oai:gup.ub.gu.se/284520 2020 oai:gup.ub.gu.se/284520 Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, et al. Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study. Eur Urol. 2020;77(2):180-8. Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, et al. Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study. Eur Urol. 2020;77(2):180-8. 10.1016/j.eururo.2019.09.027 oai:DiVA.org:uu-405337 2020 oai:DiVA.org:uu-405337 Beckmann K, Garmo H, Franck Lissbrant I, Stattin P. The value of real-world data in understanding prostate cancer risk and improving clinical care: examples from Swedish registries. Cancers (Basel). 2021;13(4). Beckmann K, Garmo H, Franck Lissbrant I, Stattin P. The value of real-world data in understanding prostate cancer risk and improving clinical care: examples from Swedish registries. Cancers (Basel). 2021;13(4). 10.3390/cancers13040875 oai:DiVA.org:uu-441121 2021 oai:DiVA.org:uu-441121 Bergengren O, Westerberg M, Holmberg L, Stattin P, Bill-Axelson A, Garmo H. Variation in prostate-specific antigen testing rates and prostate cancer treatments and outcomes in a national 20-year cohort. JAMA Netw Open. 2021;4(5):e219444. Bergengren O, Westerberg M, Holmberg L, Stattin P, Bill-Axelson A, Garmo H. Variation in prostate-specific antigen testing rates and prostate cancer treatments and outcomes in a national 20-year cohort. JAMA Netw Open. 2021;4(5):e219444. 10.1001/jamanetworkopen.2021.9444 oai:DiVA.org:uu-444389 2021 oai:DiVA.org:uu-444389 Fallara G, Alverbratt C, Garmo H, Vikman H, Hjelm Eriksson M, Lissbrant IF, et al. Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden. Acta Oncol. 2021;60(12):1589-96. Fallara G, Alverbratt C, Garmo H, Vikman H, Hjelm Eriksson M, Lissbrant IF, et al. Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden. Acta Oncol. 2021;60(12):1589-96. 10.1080/0284186x.2021.1978539 oai:gup.ub.gu.se/309212 2021 oai:gup.ub.gu.se/309212 Fallara G, Gedeborg R, Bill-Axelson A, Garmo H, Stattin P. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS One. 2021;16(7):e0255239. Fallara G, Gedeborg R, Bill-Axelson A, Garmo H, Stattin P. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS One. 2021;16(7):e0255239. 10.1371/journal.pone.0255239 oai:DiVA.org:uu-453480 2021 oai:DiVA.org:uu-453480 Fallara G, Lissbrant IF, Styrke J, Montorsi F, Gedeborg R, Sandin F, et al. Rapid ascertainment of uptake of a new indication for abiraterone by use of three nationwide health care registries in Sweden. Acta Oncol. 2021;60(1):56-60. Fallara G, Lissbrant IF, Styrke J, Montorsi F, Gedeborg R, Sandin F, et al. Rapid ascertainment of uptake of a new indication for abiraterone by use of three nationwide health care registries in Sweden. Acta Oncol. 2021;60(1):56-60. 10.1080/0284186x.2020.1847321 oai:DiVA.org:umu-178158 2021 oai:DiVA.org:umu-178158 Fallara G, Sandin F, Styrke J, Carlsson S, Lissbrant IF, Ahlgren J, et al. Prostate cancer diagnosis, staging, and treatment in Sweden during the first phase of the COVID-19 pandemic. Scand J Urol. 2021;55(3):184-91. Fallara G, Sandin F, Styrke J, Carlsson S, Lissbrant IF, Ahlgren J, et al. Prostate cancer diagnosis, staging, and treatment in Sweden during the first phase of the COVID-19 pandemic. Scand J Urol. 2021;55(3):184-91. 10.1080/21681805.2021.1910341 oai:gup.ub.gu.se/305085 2021 oai:gup.ub.gu.se/305085 Gedeborg R, Styrke J, Loeb S, Garmo H, Stattin P. Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic. PLoS One. 2021;16(10):e0255966. Gedeborg R, Styrke J, Loeb S, Garmo H, Stattin P. Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic. PLoS One. 2021;16(10):e0255966. 10.1371/journal.pone.0255966 oai:DiVA.org:uu-460911 2021 oai:DiVA.org:uu-460911 Gedeborg R, Sund M, Lambe M, Plym A, Fredriksson I, Syrjä J, et al. An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology. 2021;32(4):607-15. Gedeborg R, Sund M, Lambe M, Plym A, Fredriksson I, Syrjä J, et al. An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology. 2021;32(4):607-15. 10.1097/ede.0000000000001358 oai:DiVA.org:uu-449149 2021 oai:DiVA.org:uu-449149 George G, Vikman H, Gedeborg R, Lissbrant IF, Garmo H, Styrke J, et al. Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. Acta Oncol. 2021;60(4):459-65. George G, Vikman H, Gedeborg R, Lissbrant IF, Garmo H, Styrke J, et al. Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. Acta Oncol. 2021;60(4):459-65. 10.1080/0284186x.2021.1885058 oai:gup.ub.gu.se/302680 2021 oai:gup.ub.gu.se/302680 Godtman RA, Persson E, Cazzaniga W, Sandin F, Carlsson S, Ahlgren G, et al. Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: nationwide, population-based study. PLoS One. 2021;16(6):e0253081. Godtman RA, Persson E, Cazzaniga W, Sandin F, Carlsson S, Ahlgren G, et al. Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: nationwide, population-based study. PLoS One. 2021;16(6):e0253081. 10.1371/journal.pone.0253081 oai:gup.ub.gu.se/306221 2021 oai:gup.ub.gu.se/306221 Hermann M, Vikman H, Stattin P, Katawazai A, Gustafsson O, Styrke J, et al. Androgen deprivation therapy and the risk for inguinal hernia: an observational nested case control study. Am J Mens Health. 2021;15(6):15579883211058606. Hermann M, Vikman H, Stattin P, Katawazai A, Gustafsson O, Styrke J, et al. Androgen deprivation therapy and the risk for inguinal hernia: an observational nested case control study. Am J Mens Health. 2021;15(6):15579883211058606. 10.1177/15579883211058606 oai:DiVA.org:oru-96241 2021 oai:DiVA.org:oru-96241 Lin E, Garmo H, Van Hemelrijck M, Adolfsson J, Stattin P, Zethelius B, et al. Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study. BMC Cancer. 2021;21(1):1259. Lin E, Garmo H, Van Hemelrijck M, Adolfsson J, Stattin P, Zethelius B, et al. Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study. BMC Cancer. 2021;21(1):1259. 10.1186/s12885-021-08941-y oai:DiVA.org:uu-460220 2021 oai:DiVA.org:uu-460220 Lundström KJ, Garmo H, Gedeborg R, Stattin P, Styrke J. Short-term ciprofloxacin prophylaxis for prostate biopsy and risk of aortic aneurysm. Nationwide, population-based cohort study. Scand J Urol. 2021;55(3):221-6. Lundström KJ, Garmo H, Gedeborg R, Stattin P, Styrke J. Short-term ciprofloxacin prophylaxis for prostate biopsy and risk of aortic aneurysm. Nationwide, population-based cohort study. Scand J Urol. 2021;55(3):221-6. 10.1080/21681805.2021.1916072 oai:DiVA.org:umu-183575 2021 oai:DiVA.org:umu-183575 Orrason AW, Garmo H, Styrke J, Dickman PW, Stattin P. Comparison of relative survival and cause-specific survival in men with prostate cancer according to age and risk category: a nationwide, population-based study. Am J Epidemiol. 2021;190(10):2053-63. Orrason AW, Garmo H, Styrke J, Dickman PW, Stattin P. Comparison of relative survival and cause-specific survival in men with prostate cancer according to age and risk category: a nationwide, population-based study. Am J Epidemiol. 2021;190(10):2053-63. 10.1093/aje/kwab146 oai:DiVA.org:umu-189399 2021 oai:DiVA.org:umu-189399 Shore R, Yu J, Ye W, Lagergren J, Rutegård M, Akre O, et al. Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer. Sci Rep. 2021;11(1):13486. Shore R, Yu J, Ye W, Lagergren J, Rutegård M, Akre O, et al. Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer. Sci Rep. 2021;11(1):13486. 10.1038/s41598-021-92347-0 oai:DiVA.org:umu-185639 2021 oai:DiVA.org:umu-185639 Svensson J, Lissbrant IF, Gauffin O, Hjälm-Eriksson M, Kilany S, Fagerlund K, et al. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. Scand J Urol. 2021;55(1):1-8. Svensson J, Lissbrant IF, Gauffin O, Hjälm-Eriksson M, Kilany S, Fagerlund K, et al. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. Scand J Urol. 2021;55(1):1-8. 10.1080/21681805.2020.1851762 oai:gup.ub.gu.se/300926 2021 oai:gup.ub.gu.se/300926 Westerberg M, Larsson R, Holmberg L, Stattin P, Garmo H. Simulation model of disease incidence driven by diagnostic activity. Stat Med. 2021;40(5):1172-88. Westerberg M, Larsson R, Holmberg L, Stattin P, Garmo H. Simulation model of disease incidence driven by diagnostic activity. Stat Med. 2021;40(5):1172-88. 10.1002/sim.8833 oai:DiVA.org:uu-469809 2021 oai:DiVA.org:uu-469809 Jochems SHJ, Fritz J, Häggström C, Stattin P, Stocks T. Prediagnostic markers of insulin resistance and prostate cancer risk and death: a pooled study. Cancer Med. 2023;12(12):13732-44. Jochems SHJ, Fritz J, Häggström C, Stattin P, Stocks T. Prediagnostic markers of insulin resistance and prostate cancer risk and death: a pooled study. Cancer Med. 2023;12(12):13732-44. 10.1002/cam4.6004 oai:DiVA.org:uu-511763 2023 oai:DiVA.org:uu-511763 Alverbratt C, Vikman H, Hjälm Eriksson M, Stattin P, Franck Lissbrant I. Time difference in retrieving clinical information in Patient-overview Prostate Cancer compared to electronic health records. Scand J Urol. 2022;56(2):95-101. Alverbratt C, Vikman H, Hjälm Eriksson M, Stattin P, Franck Lissbrant I. Time difference in retrieving clinical information in Patient-overview Prostate Cancer compared to electronic health records. Scand J Urol. 2022;56(2):95-101. 10.1080/21681805.2021.2014561 oai:gup.ub.gu.se/314226 2021 oai:gup.ub.gu.se/314226 Arnsrud Godtman R, Persson E, Bergengren O, Carlsson S, Johansson E, Robinsson D, et al. Surgeon volume and patient-reported urinary incontinence after radical prostatectomy. Population-based register study in Sweden. Scand J Urol. 2022;56(5-6):343-50. Arnsrud Godtman R, Persson E, Bergengren O, Carlsson S, Johansson E, Robinsson D, et al. Surgeon volume and patient-reported urinary incontinence after radical prostatectomy. Population-based register study in Sweden. Scand J Urol. 2022;56(5-6):343-50. 10.1080/21681805.2022.2119270 oai:gup.ub.gu.se/322102 2021 oai:gup.ub.gu.se/322102 Balabanova Y, Farahmand B, Garmo H, Stattin P, Brobert G. Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden. BMJ Open. 2022;12(5):e055485. Balabanova Y, Farahmand B, Garmo H, Stattin P, Brobert G. Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden. BMJ Open. 2022;12(5):e055485. 10.1136/bmjopen-2021-055485 oai:DiVA.org:uu-477725 2022 oai:DiVA.org:uu-477725 Balabanova Y, Farahmand B, Stattin P, Garmo H, Brobert G. Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden. BMC Urol. 2022;22(1):15. Balabanova Y, Farahmand B, Stattin P, Garmo H, Brobert G. Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden. BMC Urol. 2022;22(1):15. 10.1186/s12894-022-00967-z oai:DiVA.org:uu-467399 2022 oai:DiVA.org:uu-467399 Björklund J, Stattin P, Rönmark E, Aly M, Akre O. The 90-day cause-specific mortality after radical prostatectomy: a nationwide population-based study. BJU Int. 2022;129(3):318-24. Björklund J, Stattin P, Rönmark E, Aly M, Akre O. The 90-day cause-specific mortality after radical prostatectomy: a nationwide population-based study. BJU Int. 2022;129(3):318-24. 10.1111/bju.15533 oai:DiVA.org:uu-459354 2022 oai:DiVA.org:uu-459354 Bonde TM, Westerberg M, Aly M, Eklund M, Adolfsson J, Bill-Axelson A, et al. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists. Scand J Urol. 2022;56(3):169-75. Bonde TM, Westerberg M, Aly M, Eklund M, Adolfsson J, Bill-Axelson A, et al. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists. Scand J Urol. 2022;56(3):169-75. 10.1080/21681805.2022.2070275 oai:DiVA.org:uu-474430 2022 oai:DiVA.org:uu-474430 Braide K, Kindblom J, Thellenberg Karlsson C, Stattin P, Hugosson J, Månsson M. Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study. BJU Int. 2022;130(6):799-808. Braide K, Kindblom J, Thellenberg Karlsson C, Stattin P, Hugosson J, Månsson M. Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study. BJU Int. 2022;130(6):799-808. 10.1111/bju.15769 oai:gup.ub.gu.se/319221 2022 oai:gup.ub.gu.se/319221 Gedeborg R, Garmo H, Thellenberg-Karlsson C, Fallara G, Styrke J, Franck Lissbrant I, et al. Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study. Acta Oncol. 2022;61(3):328-32. Gedeborg R, Garmo H, Thellenberg-Karlsson C, Fallara G, Styrke J, Franck Lissbrant I, et al. Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study. Acta Oncol. 2022;61(3):328-32. 10.1080/0284186x.2021.2023215 oai:gup.ub.gu.se/322455 2022 oai:gup.ub.gu.se/322455 Gedeborg R, Lindhagen L, Loeb S, Styrke J, Garmo H, Stattin P. Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer. Scand J Urol. 2022;56(2):104-11. Gedeborg R, Lindhagen L, Loeb S, Styrke J, Garmo H, Stattin P. Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer. Scand J Urol. 2022;56(2):104-11. 10.1080/21681805.2021.2019304 oai:DiVA.org:umu-190754 2022 oai:DiVA.org:umu-190754 Jochems SHJ, Häggström C, Stattin P, Järvholm B, Stocks T. Association of blood pressure with prostate cancer risk by disease severity and prostate cancer death: a pooled cohort study. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1483-91. Jochems SHJ, Häggström C, Stattin P, Järvholm B, Stocks T. Association of blood pressure with prostate cancer risk by disease severity and prostate cancer death: a pooled cohort study. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1483-91. 10.1158/1055-9965.Epi-22-0159 oai:DiVA.org:umu-198223 2022 oai:DiVA.org:umu-198223 Jochems SHJ, Stattin P, Stocks T. Reply to Paulius Bosas, Gintaras Zaleskis, and Dainius Characiejus's Letter to the Editor re: Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and risk of prostate cancer and prostate cancer death: a pooled study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033. Therapeutic monitoring in prostate cancer should involve a cotinine test in current smokers: smoking cessation remains a cornerstone in preventive health care overall and for men with prostate cancer. Eur Urol. 2022;82(4):e115. Jochems SHJ, Stattin P, Stocks T. Reply to Paulius Bosas, Gintaras Zaleskis, and Dainius Characiejus's Letter to the Editor re: Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and risk of prostate cancer and prostate cancer death: a pooled study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033. Therapeutic monitoring in prostate cancer should involve a cotinine test in current smokers: smoking cessation remains a cornerstone in preventive health care overall and for men with prostate cancer. Eur Urol. 2022;82(4):e115. 10.1016/j.eururo.2022.07.005 oai:lup.lub.lu.se:a0abcc69-6e31-4111-9181-4e260206cc67 2022 oai:lup.lub.lu.se:a0abcc69-6e31-4111-9181-4e260206cc67 Lin E, Garmo H, Van Hemelrijck M, Zethelius B, Stattin P, Hagström E, et al. Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes. JAMA Netw Open. 2022;5(8):e2225600. Lin E, Garmo H, Van Hemelrijck M, Zethelius B, Stattin P, Hagström E, et al. Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes. JAMA Netw Open. 2022;5(8):e2225600. 10.1001/jamanetworkopen.2022.25600 oai:DiVA.org:uu-482672 2022 oai:DiVA.org:uu-482672 Orrason AW, Westerberg M, Albertsen P, Styrke J, Robinson D, Garmo H, et al. Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy. PLoS One. 2022;17(11):e0277784. Orrason AW, Westerberg M, Albertsen P, Styrke J, Robinson D, Garmo H, et al. Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy. PLoS One. 2022;17(11):e0277784. 10.1371/journal.pone.0277784 oai:DiVA.org:uu-471669 2022 oai:DiVA.org:uu-471669 Stattin P. Editorial comment to 'Swedish National Guidelines on prostate cancer part I and II' by Bratt et al. How to survey adherence to guidelines by use of clinical cancer registers. Scand J Urol. 2022;56(4):285-6. Stattin P. Editorial comment to 'Swedish National Guidelines on prostate cancer part I and II' by Bratt et al. How to survey adherence to guidelines by use of clinical cancer registers. Scand J Urol. 2022;56(4):285-6. 10.1080/21681805.2022.2107069 oai:DiVA.org:uu-489380 2022 oai:DiVA.org:uu-489380 Stenman C, Abrahamsson E, Redsäter M, Gnanapragasam VJ, Bratt O. Rates of positive abdominal computed tomography and bone scan findings among men with Cambridge Prognostic Group 4 or 5 prostate cancer: a nationwide registry study. Eur Urol Open Sci. 2022;41:123-5. Stenman C, Abrahamsson E, Redsäter M, Gnanapragasam VJ, Bratt O. Rates of positive abdominal computed tomography and bone scan findings among men with Cambridge Prognostic Group 4 or 5 prostate cancer: a nationwide registry study. Eur Urol Open Sci. 2022;41:123-5. 10.1016/j.euros.2022.05.007 oai:gup.ub.gu.se/319151 2022 oai:gup.ub.gu.se/319151 Van Hemelrijck M, Ventimiglia E, Robinson D, Gedeborg R, Holmberg L, Stattin P, et al. Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Med Inform Decis Mak. 2022;22(1):35. Van Hemelrijck M, Ventimiglia E, Robinson D, Gedeborg R, Holmberg L, Stattin P, et al. Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Med Inform Decis Mak. 2022;22(1):35. 10.1186/s12911-022-01766-0 oai:DiVA.org:uu-468382 2022 oai:DiVA.org:uu-468382 Ventimiglia E, Bill-Axelson A, Adolfsson J, Aly M, Eklund M, Westerberg M, et al. Modeling disease trajectories for castration-resistant prostate cancer using nationwide population-based data. Eur Urol Open Sci. 2022;44:46-51. Ventimiglia E, Bill-Axelson A, Adolfsson J, Aly M, Eklund M, Westerberg M, et al. Modeling disease trajectories for castration-resistant prostate cancer using nationwide population-based data. Eur Urol Open Sci. 2022;44:46-51. 10.1016/j.euros.2022.07.010 oai:DiVA.org:uu-486335 2022 oai:DiVA.org:uu-486335 Ventimiglia E, Bill-Axelson A, Bratt O, Montorsi F, Stattin P, Garmo H. Long-term outcomes among men undergoing active surveillance for prostate cancer in Sweden. JAMA Netw Open. 2022;5(9):e2231015. Ventimiglia E, Bill-Axelson A, Bratt O, Montorsi F, Stattin P, Garmo H. Long-term outcomes among men undergoing active surveillance for prostate cancer in Sweden. JAMA Netw Open. 2022;5(9):e2231015. 10.1001/jamanetworkopen.2022.31015 oai:gup.ub.gu.se/321610 2022 oai:gup.ub.gu.se/321610 Ahlberg MS, Garmo H, Holmberg L, Bill-Axelson A. Variations in the uptake of active surveillance for prostate cancer and its impact on outcomes. Eur Urol Open Sci. 2023;52:166-73. Ahlberg MS, Garmo H, Holmberg L, Bill-Axelson A. Variations in the uptake of active surveillance for prostate cancer and its impact on outcomes. Eur Urol Open Sci. 2023;52:166-73. 10.1016/j.euros.2023.04.006 oai:DiVA.org:uu-509996 2023 oai:DiVA.org:uu-509996 Bonde TM, Garmo H, Stattin P, Nilsson P, Gunnlaugsson A, Swanberg D, et al. Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists. Acta Oncol. 2023;62(12):1815-21. Bonde TM, Garmo H, Stattin P, Nilsson P, Gunnlaugsson A, Swanberg D, et al. Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists. Acta Oncol. 2023;62(12):1815-21. 10.1080/0284186x.2023.2269600 oai:DiVA.org:uu-523223 2023 oai:DiVA.org:uu-523223 Corsini C, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M. Survival trend in individuals with de novo metastatic prostate cancer after the introduction of doublet therapy. JAMA Netw Open. 2023;6(10):e2336604. Corsini C, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M. Survival trend in individuals with de novo metastatic prostate cancer after the introduction of doublet therapy. JAMA Netw Open. 2023;6(10):e2336604. 10.1001/jamanetworkopen.2023.36604 oai:DiVA.org:uu-514508 2023 oai:DiVA.org:uu-514508 Crump C, Stattin P, Brooks JD, Sundquist J, Bill-Axelson A, Edwards AC, et al. Long-term risks of depression and suicide among men with prostate cancer: a national cohort study. Eur Urol. 2023;84(3):263-72. Crump C, Stattin P, Brooks JD, Sundquist J, Bill-Axelson A, Edwards AC, et al. Long-term risks of depression and suicide among men with prostate cancer: a national cohort study. Eur Urol. 2023;84(3):263-72. 10.1016/j.eururo.2023.04.026 oai:DiVA.org:uu-512857 2023 oai:DiVA.org:uu-512857 Crump C, Stattin P, Brooks JD, Sundquist J, Edwards AC, Sieh W, et al. Risks of alcohol and drug use disorders in prostate cancer survivors: a national cohort study. JNCI Cancer Spectr. 2023;7(4). Crump C, Stattin P, Brooks JD, Sundquist J, Edwards AC, Sieh W, et al. Risks of alcohol and drug use disorders in prostate cancer survivors: a national cohort study. JNCI Cancer Spectr. 2023;7(4). 10.1093/jncics/pkad046 oai:DiVA.org:uu-509286 2023 oai:DiVA.org:uu-509286 Garcia-Albeniz X, Stattin P, Westerberg M, Weinrib R, Sandstrom P, Vassilev Z. Design considerations for observational studies of drugs for advanced cancer. Pharmacoepidemiol Drug Saf. 2023;32(7):812-5. Garcia-Albeniz X, Stattin P, Westerberg M, Weinrib R, Sandstrom P, Vassilev Z. Design considerations for observational studies of drugs for advanced cancer. Pharmacoepidemiol Drug Saf. 2023;32(7):812-5. 10.1002/pds.5612 oai:DiVA.org:uu-507636 2023 oai:DiVA.org:uu-507636 Gedeborg R, Sandin F, Thellenberg-Karlsson C, Styrke J, Franck Lissbrant I, Garmo H, et al. Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden. Scand J Urol. 2023;58. Gedeborg R, Sandin F, Thellenberg-Karlsson C, Styrke J, Franck Lissbrant I, Garmo H, et al. Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden. Scand J Urol. 2023;58. 10.2340/sju.v58.9572 oai:DiVA.org:uu-524282 2023 oai:DiVA.org:uu-524282 George G, Garmo H, Adolfsson J, Elf K, Gedeborg R, Holmberg L, et al. Use of antiepileptic drugs and risk of prostate cancer: a nationwide case-control study in Prostate Cancer data Base Sweden. J Oncol. 2023;2023:9527920. George G, Garmo H, Adolfsson J, Elf K, Gedeborg R, Holmberg L, et al. Use of antiepileptic drugs and risk of prostate cancer: a nationwide case-control study in Prostate Cancer data Base Sweden. J Oncol. 2023;2023:9527920. 10.1155/2023/9527920 oai:DiVA.org:uu-514507 2023 oai:DiVA.org:uu-514507 Lin E, Garmo H, Hagström E, Van Hemelrijck M, Adolfsson J, Stattin P, et al. Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden. Br J Cancer. 2023;128(5):814-24. Lin E, Garmo H, Hagström E, Van Hemelrijck M, Adolfsson J, Stattin P, et al. Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden. Br J Cancer. 2023;128(5):814-24. 10.1038/s41416-022-02091-z oai:DiVA.org:uu-491313 2023 oai:DiVA.org:uu-491313 Robinson D, Abdulkareem R, Nasrollah D, Ljung A, Hintze P, Wallby S, et al. Frequency of biopsy and tumor grade before vs after introduction of prostate magnetic resonance imaging. JAMA Netw Open. 2023;6(8):e2330233. Robinson D, Abdulkareem R, Nasrollah D, Ljung A, Hintze P, Wallby S, et al. Frequency of biopsy and tumor grade before vs after introduction of prostate magnetic resonance imaging. JAMA Netw Open. 2023;6(8):e2330233. 10.1001/jamanetworkopen.2023.30233 oai:DiVA.org:umu-214053 2023 oai:DiVA.org:umu-214053 Shore R, Zhang J, Ye W, Stattin P, Lindblad M. Risk of colorectal adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer; a nationwide cohort study. Cancer Causes Control. 2023;34(11):949-61. Shore R, Zhang J, Ye W, Stattin P, Lindblad M. Risk of colorectal adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer; a nationwide cohort study. Cancer Causes Control. 2023;34(11):949-61. 10.1007/s10552-023-01736-5 oai:DiVA.org:uu-514510 2023 oai:DiVA.org:uu-514510 Stattin P, Westerberg M, Lissbrant IF, Eriksson MH, Kjellman A, Ullén A, et al. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2023;21(1):107.e1-.e9. Stattin P, Westerberg M, Lissbrant IF, Eriksson MH, Kjellman A, Ullén A, et al. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2023;21(1):107.e1-.e9. 10.1016/j.clgc.2022.09.002 oai:DiVA.org:uu-492640 2023 oai:DiVA.org:uu-492640 Sun M, Fritz J, Häggström C, Bjørge T, Nagel G, Manjer J, et al. Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study. J Natl Cancer Inst. 2023;115(4):456-67. Sun M, Fritz J, Häggström C, Bjørge T, Nagel G, Manjer J, et al. Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study. J Natl Cancer Inst. 2023;115(4):456-67. 10.1093/jnci/djad008 oai:DiVA.org:umu-211797 2023 oai:DiVA.org:umu-211797 Westerberg M, Beckmann K, Gedeborg R, Irenaeus S, Holmberg L, Garmo H, et al. Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidence. J Clin Epidemiol. 2023;155:22-30. Westerberg M, Beckmann K, Gedeborg R, Irenaeus S, Holmberg L, Garmo H, et al. Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidence. J Clin Epidemiol. 2023;155:22-30. 10.1016/j.jclinepi.2022.12.008 oai:DiVA.org:uu-492637 2023 oai:DiVA.org:uu-492637 Ahlberg M, Garmo H, Stattin P, Gedeborg R, Edlund C, Holmberg L, et al. Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control study. Scand J Urol. 2024;59:63-9. Ahlberg M, Garmo H, Stattin P, Gedeborg R, Edlund C, Holmberg L, et al. Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control study. Scand J Urol. 2024;59:63-9. 10.2340/sju.v59.34803 oai:DiVA.org:uu-515871 2024 oai:DiVA.org:uu-515871 Corsini C, Bergengren O, Carlsson S, Garmo H, Hjelm-Eriksson M, Fransson P, et al. Patient-reported side effects 1 year after radical prostatectomy or radiotherapy for prostate cancer: a register-based nationwide study. Eur Urol Oncol. 2024;7(3):605-13. Corsini C, Bergengren O, Carlsson S, Garmo H, Hjelm-Eriksson M, Fransson P, et al. Patient-reported side effects 1 year after radical prostatectomy or radiotherapy for prostate cancer: a register-based nationwide study. Eur Urol Oncol. 2024;7(3):605-13. 10.1016/j.euo.2023.12.007 oai:DiVA.org:uu-533106 2024 oai:DiVA.org:uu-533106 Crump C, Stattin P, Brooks JD, Sundquist J, Edwards AC, Sundquist K, et al. Risks of depression, anxiety, and suicide in partners of men with prostate cancer: a national cohort study. J Natl Cancer Inst. 2024;116(5):745-52. Crump C, Stattin P, Brooks JD, Sundquist J, Edwards AC, Sundquist K, et al. Risks of depression, anxiety, and suicide in partners of men with prostate cancer: a national cohort study. J Natl Cancer Inst. 2024;116(5):745-52. 10.1093/jnci/djad257 oai:lup.lub.lu.se:b19cc7e9-17a4-4a3e-b4f4-f4b52fad3739 2024 oai:lup.lub.lu.se:b19cc7e9-17a4-4a3e-b4f4-f4b52fad3739 Crump C, Stattin P, Brooks JD, Sundquist J, Sieh W, Sundquist K. Mortality risks associated with depression in men with prostate cancer. Eur Urol Oncol. 2024;S2588-9311(24)00089-0. Crump C, Stattin P, Brooks JD, Sundquist J, Sieh W, Sundquist K. Mortality risks associated with depression in men with prostate cancer. Eur Urol Oncol. 2024;S2588-9311(24)00089-0. 10.1016/j.euo.2024.03.012 2024 Egevad L, Micoli C, Delahunt B, Samaratunga H, Orrason AW, Garmo H, et al. Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. Virchows Arch. 2024;484(6):995-1003. Egevad L, Micoli C, Delahunt B, Samaratunga H, Orrason AW, Garmo H, et al. Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. Virchows Arch. 2024;484(6):995-1003. 10.1007/s00428-024-03810-y oai:prod.swepub.kib.ki.se:238683251 2024 oai:prod.swepub.kib.ki.se:238683251 Egevad L, Micoli C, Samaratunga H, Delahunt B, Garmo H, Stattin P, et al. Prognosis of Gleason score 9-10 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. Eur Urol Oncol. 2024;7(2):213-21. Egevad L, Micoli C, Samaratunga H, Delahunt B, Garmo H, Stattin P, et al. Prognosis of Gleason score 9-10 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. Eur Urol Oncol. 2024;7(2):213-21. 10.1016/j.euo.2023.11.002 oai:prod.swepub.kib.ki.se:237978024 2024 oai:prod.swepub.kib.ki.se:237978024 Franck Lissbrant I, Styrke J, Törnblom M, Hjelm Eriksson M, Axén E, Stattin P. Prostatacancerregistret – för patienter, sjukvård och forskning. Läkartidningen. 2024;121:23196. Franck Lissbrant I, Styrke J, Törnblom M, Hjelm Eriksson M, Axén E, Stattin P. Prostatacancerregistret – för patienter, sjukvård och forskning. Läkartidningen. 2024;121:23196. 2024 Fritz J, Jochems SHJ, Bjørge T, Wood AM, Häggström C, Ulmer H, et al. Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts. Br J Cancer. 2024;130(2):308-16. Fritz J, Jochems SHJ, Bjørge T, Wood AM, Häggström C, Ulmer H, et al. Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts. Br J Cancer. 2024;130(2):308-16. 10.1038/s41416-023-02526-1 oai:DiVA.org:uu-531609 2024 oai:DiVA.org:uu-531609 Lundberg F, Robinson D, Bratt O, Fallara G, Lambe M, Johansson ALV. Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer. Acta Oncol. 2024;63:95-104. Lundberg F, Robinson D, Bratt O, Fallara G, Lambe M, Johansson ALV. Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer. Acta Oncol. 2024;63:95-104. 10.2340/1651-226x.2024.26189 oai:prod.swepub.kib.ki.se:238505996 2024 oai:prod.swepub.kib.ki.se:238505996 Scilipoti P, Liedberg F, Garmo H, Wilberg Orrason A, Stattin P, Westerberg M. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostatectomy. A nationwide population-based study. Scand J Urol. 2024;59:98-103. Scilipoti P, Liedberg F, Garmo H, Wilberg Orrason A, Stattin P, Westerberg M. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostatectomy. A nationwide population-based study. Scand J Urol. 2024;59:98-103. 10.2340/sju.v59.40001 oai:DiVA.org:uu-534084 2024 oai:DiVA.org:uu-534084 Stattin P, Fleming S, Lin X, Lefresne F, Brookman-May SD, Mundle SD, et al. Population-based study of disease trajectory after radical treatment for high-risk prostate cancer. BJU Int. 2024;134(1):96-102. Stattin P, Fleming S, Lin X, Lefresne F, Brookman-May SD, Mundle SD, et al. Population-based study of disease trajectory after radical treatment for high-risk prostate cancer. BJU Int. 2024;134(1):96-102. 10.1111/bju.16362 oai:DiVA.org:umu-224254 2024 oai:DiVA.org:umu-224254 Strömberg U, Berglund A, Carlsson S, Thellenberg Karlsson C, Lambe M, Lissbrant IF, et al. Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden. Int J Cancer. 2024;155(4):637-45. Strömberg U, Berglund A, Carlsson S, Thellenberg Karlsson C, Lambe M, Lissbrant IF, et al. Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden. Int J Cancer. 2024;155(4):637-45. 10.1002/ijc.34932 oai:gup.ub.gu.se/336383 2024 oai:gup.ub.gu.se/336383 Thomsen FF, Garmo H, Egevad L, Stattin P, Brasso K. Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancer. Scand J Urol. 2024;59:76-83. Thomsen FF, Garmo H, Egevad L, Stattin P, Brasso K. Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancer. Scand J Urol. 2024;59:76-83. 10.2340/sju.v59.34015 oai:DiVA.org:uu-530586 2024 oai:DiVA.org:uu-530586 Westerberg M, Garmo H, Robinson D, Stattin P, Gedeborg R. Target trial emulation using new comorbidity indices provided risk estimates comparable to a randomized trial. J Clin Epidemiol. 2024;174:111504. Westerberg M, Garmo H, Robinson D, Stattin P, Gedeborg R. Target trial emulation using new comorbidity indices provided risk estimates comparable to a randomized trial. J Clin Epidemiol. 2024;174:111504. 10.1016/j.jclinepi.2024.111504 oai:DiVA.org:uu-540054 2024 oai:DiVA.org:uu-540054 Westerberg M, Irenaeus S, Garmo H, Stattin P, Gedeborg R. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: nationwide, population-based register study. PLoS One. 2024;19(1):e0296804. Westerberg M, Irenaeus S, Garmo H, Stattin P, Gedeborg R. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: nationwide, population-based register study. PLoS One. 2024;19(1):e0296804. 10.1371/journal.pone.0296804 oai:DiVA.org:uu-526555 2024 oai:DiVA.org:uu-526555